<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004410" GROUP_ID="SCHIZ" ID="689701052110545941" MERGED_FROM="" MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2 beta.&lt;/p&gt;&lt;p&gt;Protocol and review published together.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 09:51:40 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving">
<TITLE>New generation antipsychotics for first episode schizophrenia</TITLE>
<CONTACT MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="1184FC3782E26AA201DC7B3ED86B19FD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Johannes</FIRST_NAME><LAST_NAME>Hamann</LAST_NAME><POSITION>Assistenzarzt</POSITION><EMAIL_1>j.hamann@lrz.tum.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6683</PHONE_1><FAX_1>+49-89-4140-6688</FAX_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-31 10:19:29 +0000" MODIFIED_BY="John  Rathbone" NOTES="&lt;p&gt;Minor update: 8/20/03&lt;/p&gt;" NOTES_MODIFIED="2008-10-31 10:19:29 +0000" NOTES_MODIFIED_BY="John  Rathbone">
<UP_TO_DATE>
<DATE DAY="21" MONTH="7" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="7" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2002"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="17" MONTH="10" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:34:55 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Federal Ministry for Education and Research (BMBF)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-31 10:26:14 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-31 10:19:44 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-31 10:19:44 +0000" MODIFIED_BY="[Empty name]">New generation antipsychotics for first episode schizophrenia</TITLE>
<SUMMARY_BODY>
<P>A new generation of antipsychotics, drugs such as olanzapine and risperidone are recommended for people with a first episode of schizophrenia. Currently, the quality of information is too limited to come to any firm conclusions. A number of ongoing studies should provide more and better information in the near future.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The new generation antipsychotics are associated with a lower risk of adverse effects compared with drugs such as haloperidol. Many treatment guidelines recommend the use of new generation ('atypical') antipsychotic drugs for people with a first episode of schizophrenia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the effects of the new generation antipsychotics for people with a first episode of schizophrenia or schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The reviewers searched the Cochrane Schizophrenia Group's register (March 2002) and the included and excluded studies tables of relevant Cochrane reviews, references of all relevant studies, contacted industry and authors of relevant studies to identify further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing new generation antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, zotepine) with conventional antipsychotics for people with a first episode of schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Citations and, where possible, abstracts were independently inspected by three reviewers, papers ordered, re-inspected and quality assessed. We independently extracted data but excluded them if loss to follow up was greater than 50%. For homogeneous dichotomous data, we calculated the relative risk (RR), the 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT), on an intention-to-treat basis. For continuous data, reviewers calculated weighted mean differences (WMD).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We include two short-term studies (total n=266), one of which was a report of a sub-group of a larger study. One compared risperidone with an average of 6 mg/day haloperidol and the other olanzapine with an average of 11 mg/day haloperidol. Compared with olanzapine, significantly more people receiving haloperidol left the study early (n=83, 1 RCT, RR 0.43 CI 0.3 to 0.7, NNH 3 CI 2 to 8). This was not so for the risperidone versus haloperidol comparison (n=183, 1 RCT, RR=0.7 CI 0.4 to 1.1). In terms of global effects, studies reported no differences between risperidone and haloperidol (n=183, RR not much improved 1.0 CI 0.6 to 1.5), and olanzapine and the same control (n=83, RR needing at least one dose of benzodiazepine 0.8 CI 0.5 to 1.1). More people allocated to olanzapine had clinically significant improvement in mental state compared with those given haloperidol (n=83, RR no 'clinically significant improvement' 0.45 CI 0.3 to 0.7, NNH 3 CI 2 to 6). In the risperidone study, however, no such difference was apparent (n=183, RR 'no clinically significant improvement in mental state' 0.85 CI 0.6 to 1.2). Significantly more people given haloperidol (4-16mg) experienced at least one adverse event when compared with risperidone (4-16mg) (n=183, RR 0.9 CI 0.8 to 0.98, NNH 8 CI 4 to 50). Use of anticholinergic medication for extrapyramidal adverse events was less prevalent for people allocated either olanzapine (n=83, RR 0.3 CI 0.2 to 0.7, NNH 4 CI 2 to 14) or risperidone (n=183, RR 0.7 CI 0.5 to 0.9, NNH 4 CI 3 to 9) compared with those given haloperidol.</P>
<P>There are no data at all on outcomes such as compliance, cost, social and cognitive functioning, relapse, rehospitalisation, or quality of life. There are no medium to long-term data. Eight ongoing studies may provide more information.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The results of this review are inconclusive. Whether the use of new generation antipsychotics really makes the treatment less off putting and enhances long-term compliance is unclear. Pragmatic, well-designed and reported long-term trials would be useful to answer this question.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-31 10:26:14 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>The first episode of schizophrenia is a difficult stage of the illness. Most of the individuals with a first episode of schizophrenia experience a prodromal phase where symptoms like social withdrawal, loss of interest in work or school, unusual behaviour or outbursts of anger develop gradually, even though the onset may be sudden (<LINK REF="REF-Herz-2000" TYPE="REFERENCE">Herz 2000</LINK>). Very early in the illness people with schizophrenia are often so convinced of the reality of their psychotic experiences that they are frequently reluctant to take antipsychotic drugs (<LINK REF="REF-Oehl-2000" TYPE="REFERENCE">Oehl 2000</LINK>). As the duration of untreated psychosis prior to first psychiatric treatment adversely influences the long-term outcome in schizophrenia, the importance of early treatment in first-episode schizophrenic patients is apparent (<LINK REF="REF-Bottlender-2003" TYPE="REFERENCE">Bottlender 2003</LINK>). Given that schizophrenia is often a chronic disorder that necessitates long-term maintenance treatment with antipsychotic drugs, it is crucial to build a firm alliance between doctors, patients and patients families. </P>
<P>Treatment guidelines generally recommend using new generation antipsychotics such as olanzapine or risperidone for those with a first episode of the illness (<LINK REF="REF-McEvoy-1999" TYPE="REFERENCE">McEvoy 1999</LINK>, <LINK REF="REF-NICE-2002" TYPE="REFERENCE">NICE 2002</LINK>). This recommendation is based on the idea that the new generation antipsychotic drugs are all associated with a relatively low occurrence of movement disorders such as rigidity, mask-like appearance, tremor, stooped shuffling gait, and other effects such as inner feeling of restlessness (akathisia) and acute spinal and ocular rigidity (acute dystonias). Because of this the new drugs are often called 'atypical', although scientifically this concept is difficult to define and should be avoided (<LINK REF="REF-Reynolds-1997" TYPE="REFERENCE">Reynolds 1997</LINK>). For example, risperidone can cause dose-dependent movement disorders (<LINK REF="REF-Fleischhacker-2001" TYPE="REFERENCE">Fleischhacker 2001</LINK>), and so does not seem to conform completely with even the broad definition of 'atypicality' mentioned above . On the other hand, if receptor binding profiles are used to define atypicality, some of the old drugs, for example molindone or loxapine, could be considered 'atypical'.</P>
<P>We tried to use a scientific definition for 'atypicality' for this review, namely an antipsychotic drug that in animal models does not induce catalepsy (an indicator for extrapyramidal effects) at effective doses (see Types of Interventions). Although there is no uniform clear-cut definition of atypicality, the impression is that most clinicians tend to consider new and expensive antipsychotics as 'atypical', and it is these new and expensive drugs which are being recommended for the treatment of first episode schizophrenic patients.</P>
<P>Technical background<BR/>The reasons for the lower occurrence of extrapyramidal adverse effects associated with the new generation antipsychotic drugs are not absolutely clear. A frequent explanation is that compared to high potency antipsychotics such as haloperidol, which is a rather selective dopamine receptor antagonist, the new generation antipsychotics block central serotonin receptors more than central dopamine receptors (<LINK REF="REF-Schotte-1996" TYPE="REFERENCE">Schotte 1996</LINK>). This can mitigate the extrapyramidal effects, which are induced by the blockade of dopamine receptors. </P>
<P>The pharmacological profile of clozapine shows a high affinity for the serotonin 5-HT2A, 5-HT2C, 5-HT6, 5-HT7 and D4 receptors and a low affinity for D2 receptors (<LINK REF="REF-Meltzer-1994" TYPE="REFERENCE">Meltzer 1994</LINK>). Risperidone has a well-described mechanism of action, a high ratio of 5HT2 to D2 receptor blockade (<LINK REF="REF-Curtis-1995" TYPE="REFERENCE">Curtis 1995</LINK>). Amisulpride, an exception among the new antipsychotics, is a pure dopamine receptor antagonist. Here, the current explanation for its low risk of extrapyramidal effects is that it blocks dopamine receptors selectively in the limbic system where the cause of the symptoms of the disorder are suspected, but not in the striatum (<LINK REF="REF-Scatton-1997" TYPE="REFERENCE">Scatton 1997</LINK>). Amisulpride seems to share this property with olanzapine and quetiapine, which, in addition to their effects on serotonin receptors, also quite selectively block dopamine receptors in the mesolimbic system (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the effects of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone and zotepine for the treatment of those with a first episode of schizophrenia or related psychoses in comparison with placebo or conventional antipsychotic medication.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-31 10:26:14 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-31 10:25:08 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials. Where a trial was described as 'double-blind' but it was implied that the study was randomised, these trials were included in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then they were included in the final analysis. If there was a substantive difference, only clearly randomised trials were utilised and the results of the sensitivity analysis described in the text. Quasi-randomised studies, such as those allocating by using alternate days of the week, were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with a first episode of schizophrenia or related disorders such as schizophreniform, schizoaffective or delusional disorder, diagnosed by any criteria. Those with 'serious mental illness' or 'psychotic illness' were also included as long as they were first episode according to the original authors' criteria. If possible, people with dementingillnesses, depression and problems primarily associated with substance misuse were excluded. Where a trial included people with multiple episodes, but presented data separately for those in their first episode, these were included. In studies where information for people with first and multiple episodes were not separated, if 80% of participants were in their first episode these data were also included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. New generation antipsychotic drugs: amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, zotepine: any dose or pattern of administration.</P>
<P>This selection needs further clarification. There is no universal definition for 'atypical' or 'new generation' antipsychotic drugs. For the purpose of this review we tried to apply a relatively scientific definition for 'atypicality': an antipsychotic drug that in animal models does not induce catalepsy (an indicator for extrapyramidal side-effects) at effective doses. <LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK> reported such data from experiments in rats: haloperidol inhibited hypermotility and stereotypies induced by dopaminergic drugs but also induced catalepsy in rats in similar doses. In contrast to haloperidol, the new generation antipsychotics clozapine, olanzapine, quetiapine, risperidone, sertindole and ziprasidone inhibited hypermobility and hypermotility induced by amphetamine but did not induce catalepsy (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). Similar effects have been shown for amisulpride (<LINK REF="REF-Perrault-1997" TYPE="REFERENCE">Perrault 1997</LINK>) and zotepine (<LINK REF="REF-Gattaz-1994" TYPE="REFERENCE">Gattaz 1994</LINK>). We are not aware of such animal data for sulpiride, however, since it is a substituted benzamide with a very similar chemical structure and clinical effects to that of amisulpride we included it in this review. Sertindole was excluded from the review, because it was withdrawn from the market some years ago. Aripiprazole was not included because it was not available when the protocol was written.</P>
<P>We want to stress that although many researchers would probably agree with this selection, others would not and would probably come up with further suggestions. For example, molindone and loxapine are old antipsychotic drugs which might be considered 'atypicals', because they have similar receptor binding profiles to some of the new generation antipsychotics. However, we are not aware of any experiments in animals having been carried out with these drugs. Cochrane reviews of molindone and loxapine (<LINK REF="REF-Fenton-2002" TYPE="REFERENCE">Fenton 2002</LINK>, <LINK REF="REF-Bagnall-2002" TYPE="REFERENCE">Bagnall 2002</LINK>) did not find that they had a lower risk of extrapyramidal side-effects than conventional antipsychotics.<BR/>
<B>
<BR/>
</B>2. Conventional antipsychotic drugs (e.g. haloperidol, flupenthixol, fluphenazine, chlorpromazine, pimozide etc.): any dose or pattern of administration.</P>
<P>3. Placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-31 10:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>All outcomes were reported for the short term (up to 12 weeks), medium term (13-26 weeks), and long term (more than 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-31 10:23:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Service utilisation outcomes<BR/>1.1 Hospital admission</P>
<P>2. Behaviour<BR/>2.1 Compliance with treatment - as defined by each of the studies</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-31 10:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death: suicide or natural causes</P>
<P>2. Leaving the study early</P>
<P>3. Service utilisation outcomes<BR/>3.1 Days in hospital<BR/>3.2 Change in hospital status</P>
<P>4. Clinical response<BR/>4.1 Average score/change in global state<BR/>4.2 No clinically significant response in mental state - as defined by each of the studies<BR/>4.3 Average score/change in mental state<BR/>4.4 No clinically significant response on positive symptoms - as defined by each of the studies<BR/>4.5 Average score/change in positive symptoms<BR/>4.6 No clinically significant response on negative symptoms- as defined by each of the studies<BR/>4.7 Average score/change in negative symptoms.<BR/>4.8 No clinically significant response on depressive symptoms- as defined by each of the studies<BR/>4.9 Average score/change in depressive symptoms</P>
<P>5. Behaviour<BR/>5.1 No clinically significant response in behaviour (e.g. aggressive behaviour, behaviour on the ward etc.) - as defined by each of the studies<BR/>5.2 Average score/change in behaviour</P>
<P>6. Extrapyramidal adverse effects<BR/>6.1 Incidence of use of antiparkinson drugs<BR/>6.2 Clinically significant extrapyramidal adverse effects - as defined by each of the studies<BR/>6.3 Average score/change in extrapyramidal adverse effects</P>
<P>7. Other adverse effects, general and specific<BR/>7.1 Numbers leaving the studies early due to adverse effects<BR/>7.2 Anticholinergic effects<BR/>7.3 Antihistamine effects<BR/>7.4 Cardiac effects<BR/>7.5 Prolactin related symptoms</P>
<P>8. Social functioning<BR/>8.1 No clinically significant response in social functioning - as defined by each of the studies<BR/>8.2 Average score/change in social functioning</P>
<P>9. Economic outcomes</P>
<P>10. Quality of life/satisfaction with care for either recipients of care or carers<BR/>10.1 No clinically significant change in quality of life/ satisfaction - as defined by each of the studies<BR/>10.2 Average score/change in quality of life/ satisfaction<BR/>10.3 Employment status</P>
<P>11. Cognitive functioning</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-31 10:26:14 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-31 10:26:11 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Schizophrenia Group's Register (March 2002) was searched with the phrase:</P>
<P>[(*first* or *primary* or *initial* or *original*) and (amisulprid* or amitrex or deniban* or socian* or solian* or sulanid* or sulamid* or zyprex* or olanzapin* or quetiapine or seroquel or ICI-204636 or (ICI and 204636) or ICI204636 or risperidone or risperdal or 9-OH-risperidone or ziprasidone or cp-88059 or abilit or championyl or coolspan or col-sulpir or digton or dixibon or dobren or dogmatil or dolmatil or drominetas or eglonyl or equilid or eusulpid or guastil or isnamid or kapiride or lavodina or lebopride or lusedan or miradol or mirbanil or misulvan or neuromyfar or normum or omperan or psicocen or quiridil or sato or sernevin or sicofrenol or sulpiride or sulpisedan or suprium or sursumid or tepavil or tonofit or ulpir or vipral or zotepine or lodopin or nipolept or zopite or setous or majorpin or clozapine or clozaril or leponex)] in title or abstract or index terms in REFERENCE.</P>
<P>This register is compiled by methodical searches of BIOSIS CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings (see Group Module).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-31 10:25:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Reviews<BR/>We inspected the included and excluded tables of each relevant Cochrane review in the hope of finding studies where sub-groups of people with first episode psychoses had been reported on separately.</P>
<P>2. Reference searching<BR/>We inspected references of all identified studies for further studies.</P>
<P>3. Personal contact<BR/>We contacted the first author of each included study for more information regarding unpublished trials.</P>
<P>4. Pharmaceutical industry<BR/>We contacted the manufacturers of the new generation antipsychotics listed for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>Three reviewers (SL, CR, JH) independently inspected all citations of studies identified by the search. Where disagreement occurred this was resolved by discussion with WK, or, when there was still doubt, reviewers acquired the full article for further inspection. Once the full articles were obtained SL decided whether they met review criteria and this was checked by CR and JH. Once again, disagreement was resolved by discussion, but if doubt remained, the study was put on the list of those awaiting assessment, pending acquisition of more information.</P>
<P>2. Quality assessment<BR/>Reviewers used criteria in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>) to assess trial quality. This simple set of criteria is based on evidence of strong association between overestimation of effect and poor concealment of allocation, and is defined as follows:</P>
<P>A. Low risk of bias (adequate allocation concealment);<BR/>B. Moderate risk of bias (some doubt about the results);<BR/>C. High risk of bias (inadequate allocation concealment).</P>
<P>The Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) measures a wider range of factors that impact on the quality of a trial. The scale includes three items:</P>
<P>1. Was the study described as randomised?<BR/>2. Was the study described as double blind?<BR/>3. Was there a description of withdrawals and dropouts?</P>
<P>Each item scores one point if the answer is positive and an additional point for the first two items if the means of randomisation/blinding is described. In addition, a point can be deducted if either the randomisation or the blinding/masking described were inadequate.</P>
<P>For the purpose of analysis of this review, studies were included if they met criteria A and B of the Handbook. Studies not described as randomised by the authors were given a C rating and excluded. The Jadad scale was not used to exclude studies, but it was used for a further description of the quality of the included trials.</P>
<P>3. Data extraction <BR/>3.1 Reliable extraction<BR/>CR, SL and JH independently extracted data from selected trials. When disputes arose we attempted resolution by discussion. If doubt remained and further information was necessary to resolve the dilemma, we did not enter the data, but contacted the authors of the studies for further information.</P>
<P>3.2 Multiple doses<BR/>If several doses of a new antipsychotic were compared with one dose of the control drug, the different dose groups of the new antipsychotic were pooled. For example, for dichotomous data, all participants treated with a new antipsychotic were considered as a single group. For continuous data, the mean of all participants on the new antipsychotic was used in the comparisons. </P>
<P>4. Data synthesis <BR/>4.1 Data types<BR/>Outcomes were assessed using continuous (for example, average changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan software does not support categorical data, so they were presented only in the text of the review.</P>
<P>4.2 Incomplete data<BR/>With the exception of the outcome of leaving the study early, trial outcomes studies were not included if overall more than 50% of people in short (up to 12 weeks) and medium-term studies (up to 26 weeks) or 60% of people in long-term studies were not reported in the final analysis. We felt that with such a great degree of attrition, great assumptions would have to be made, and these would threaten the validity of the findings. However, since there is no clear evidence as to the degree of study attrition which would make its inclusion inappropriate due to bias, all studies were combined in a sensitivity analysis. </P>
<P>4.3 Dichotomous/binary data<BR/>4.3.1 Defining cut offs: where the original authors of the studies reported outcomes such as 'clinically improved' or 'not clinically improved', based on their clinical judgement, predetermined criteria, or on any scale, this was recorded in RevMan. If data were from a rater not clearly stated to be independent, then it was included if it did not change the results; otherwise it was presented separately with a label 'prone to bias'. Where possible, efforts were made to convert relevant categorical or continuous outcome measures to dichotomous data by identifying cut off points on rating scales and dividing subjects accordingly into groups. This was done with the cut off points 'moderate or severe impairment' for end of study data or 'no better or worse' for change data. For example the Brief Psychiatric Rating Scale (BPRS - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is frequently used as a measure of change of symptoms in studies. The reviewers defined a 50% change on this particular scale as clinically important, although it was recognised that for many people, especially those with chronic or severe illnesses, a less rigorous definition of important improvement, for example, 20% on the BPRS, would be equally valid. If individual patient data were available the 50% cut off was used. For the Clinical Global Impression (<LINK REF="REF-Guy-1970" TYPE="REFERENCE">Guy 1970</LINK>) 'at least much improved' was used as a cut-off.</P>
<P>4.3.2 Intention-to-treat analysis: the review presents an intention to treat analysis. As long as more than 50% of people in short and medium term studies and 40% in long term studies completed the trial, everyone allocated to the intervention was counted whether or not they completed follow up. It was assumed that those who left the study early had no change in their outcome.</P>
<P>4.3.3 Summary statistic: the review uses relative risk (RR) and 95% confidence interval (CI) based on a fixed effects model in case of homogeneous data and based on a random effects model in case of heterogeneous data. Given that the random effects model is generally more conservative, because it takes into account differences between studies, even if heterogeneity is not statistically significant, all outcomes were also examined using the random effects model in order to corroborate the findings. It has also been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. Data were again inspected, however, to see if analysis using a Mantel-Haenszel odds ratio made a substantive difference. Where possible, reviewers estimated the number needed to treat (NNT) and the number needed to harm (NNH), respectively, calculating 1/risk difference.</P>
<P>4.4 Continuous data<BR/>4.4.1 Intention-to-treat versus completer analyses: given that all the new antipsychotics have been developed relatively recently, it was assumed that in many cases an intention-to-treat analysis would be available, so that continuous data were analysed on this basis. </P>
<P>4.4.2 Rating scales: a wide range of instruments is available for measuring mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. Some minimum standards had to be set for outcome instruments. Continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal, because unpublished scales may be a source of bias (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), if the instrument was either a self report or completed by an independent rater or relative (not the therapist), and if the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, such data were labelled as 'prone to bias'. </P>
<P>4.4.3 Normal distribution of data: mental health continuous data are often not normally distributed. Most statistics assume a normal distribution. To avoid including non-normally distributed data in the statistical analysis, the following criteria were applied to all data before inclusion:</P>
<P>a. Standard deviations and means were reported or derivable from data in the paper, or were obtainable from the authors of the studies.<BR/>b. When a scale started at zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied to them. <BR/>c. When continuous data are presented on a scale which includes the possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale end point data, which typically cannot have negative values. If end point data were not available, reviewers chose to use change data, because the statistics used in Metaview are rather robust in regard to skew.<BR/>d. If a scale started with a positive value (such as PANSS, which can have values from 30-210) the calculation described above in (b) was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.4.4 Endpoint versus change data: endpoint scale-derived data are finite, ranging from one score to another. Change data are more problematic and for them the rule described above does not apply. There is no method for deciding whether change data are skewed or not. We decided to present them in MetaView; but where both endpoint and change were available for the same outcome, we presented the former in preference. </P>
<P>4.4.5 Summary statistic: for continuous outcomes, a weighted mean difference (WMD) between groups was estimated. Again, a fixed effects model was used for homogeneous data and a random effects model for heterogeneous data. </P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) - whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated - causing type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Secondly, RevMan does not currently support meta-analytic pooling of clustered dichotomous data, even when these are correctly analysed by the authors of primary studies, since the 'design effect' (a statistical correction for clustering) cannot be incorporated. </P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol - to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect. We have sought statistical advice from the MRC Biostatistics Unit, Cambridge, UK on this. Dr Julian Higgins advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC]. Should the ICC not be reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>4.6 Sensitivity analyses <BR/>We analysed whether the inclusion of trials with drop-out rates higher than 50% for short-term and higher than 60% for long-term studies led to different results.</P>
<P>5. Heterogeneity <BR/>Reviewers assessed heterogeneity between trial results both by inspection of graphical presentations and by calculating a Chi square test of heterogeneity. A significance level less than 0.1 was interpreted as evidence of heterogeneity. If heterogeneity was present, the reviewers performed a sensitivity analysis to the presence or absence of these data. </P>
<P>6. Addressing publication bias <BR/>Data from all identified and selected trials were entered into a funnel graph (trial effect versus trial size) in an attempt to investigate overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>7. Tables and figures <BR/>Where possible, data were entered into RevMan so the area to the left of the line of no effect indicated a favourable outcome for the new generation antipsychotics.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Please also see Tables of included and excluded studies.</P>
<P>1. Excluded studies<BR/>The main reasons for exclusion were that studies did not involve people in their first episode of illness (n=27). Some trials did not randomise or randomised inadequately (n=9) and two trials did not include a treatment group with another antipsychotic drug or placebo.</P>
<P>2. Studies awaiting assessment <BR/>The authors of ten studies were contacted for further information, but no replies have been received. There are two broad groups of studies in the awaiting assessment section. In one group it is unclear whether participants were indeed people with a first episode of schizophrenia (<LINK REF="STD-Gordon-1994" TYPE="STUDY">Gordon 1994</LINK>, <LINK REF="STD-Kumra-1996" TYPE="STUDY">Kumra 1996</LINK> and <LINK REF="STD-van-Bruggen-1999" TYPE="STUDY">van Bruggen 1999</LINK>). The second group of studies does seem to involve relevant participants but no data, or no usable data, is currently available (<LINK REF="STD-Edwards-1999" TYPE="STUDY">Edwards 1999</LINK>, <LINK REF="STD-Glenthoj-2001" TYPE="STUDY">Glenthoj 2001</LINK>, <LINK REF="STD-Jarboe-2001" TYPE="STUDY">Jarboe 2001</LINK>, <LINK REF="STD-Keefe-2001" TYPE="STUDY">Keefe 2001</LINK>, <LINK REF="STD-Lavalaye-1999" TYPE="STUDY">Lavalaye 1999</LINK>, <LINK REF="STD-Lieberman-2000" TYPE="STUDY">Lieberman 2000</LINK>, <LINK REF="STD-Lieberman-2001" TYPE="STUDY">Lieberman 2001</LINK>). We look forward to receiving more data from these important trials.</P>
<P>3. Ongoing and planned studies<BR/>Eight ongoing or planned studies were identified. <LINK REF="STD-Gaebel-2000" TYPE="STUDY">Gaebel 2000</LINK> compares haloperidol with risperidone in 140 first episode patients for the first year, in the second year continued drug treatment is compared with drug discontinuation. In <LINK REF="STD-Kane-2001" TYPE="STUDY">Kane 2001</LINK> participants receive olanzapine, risperidone or ziprasidone for three years. <LINK REF="STD-M_x00f6_ller-2000" TYPE="STUDY">Möller 2000</LINK> compares haloperidol with risperidone in 360 people with first episode schizophrenia. In <LINK REF="STD-Reveley-2000" TYPE="STUDY">Reveley 2000</LINK> 26 participants with early psychotic symptoms are treated with haloperidol or risperidone. <LINK REF="STD-Rosebush-2000" TYPE="STUDY">Rosebush 2000</LINK> will treat those with a first episode of schizophrenia with haloperidol or olanzapine. <LINK REF="STD-Schooler-1997a" TYPE="STUDY">Schooler 1997a</LINK> is following 500 participants with early psychosis for up to four years after at least one year of treatment with haloperidol or risperidone. <LINK REF="STD-Sharma-2000" TYPE="STUDY">Sharma 2000</LINK> will compare haloperidol with risperidone in participants with first episode psychotic disorder and will follow them for two to four years. In <LINK REF="STD-Sharma-2000a" TYPE="STUDY">Sharma 2000a</LINK> the acute and long-term efficacy of olanzapine versus haloperidol for people with a first episode psychotic disorder will be assessed. These important studies are eagerly awaited and illustrate the relevance of the question this review addresses. </P>
<P>4. Included studies<BR/>We identified two studies for inclusion in this review.</P>
<P>4.1 Study design<BR/>
<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> and <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> both used a parallel group design.</P>
<P>4.2 Length of trials<BR/>
<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> was a short-term study of six weeks duration. The data for the <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> study were taken from the 6-week acute phase of a large, prospective, international, multicenter, double-blind, 14-month study (<LINK REF="REF-Tollefson-1997" TYPE="REFERENCE">Tollefson 1997</LINK>). <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> evaluated a subpopulation of people in their first episode of schizophrenia from <LINK REF="REF-Tollefson-1997" TYPE="REFERENCE">Tollefson 1997</LINK>.</P>
<P>4.3 Participants<BR/>These studies included a total of 266 people (<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> - 183 people, <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> - 83). Most participants were diagnosed with schizophreniform disorder (n=192), there were some with a diagnosis of schizophrenia (n=67) and a few were diagnosed with schizoaffective disorder (n=7). Both studies examined only participants with a first psychotic episode.</P>
<P>4.4. Interventions<BR/>
<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> compared flexible doses of risperidone and haloperidol. A starting dose of 2 mg twice daily was increased in increments of 2 mg/day to a maximum of 8 mg twice daily. <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> compared olanzapine with haloperidol. In this case participants started with 5 mg/day and after each 7-day period the dose was adjusted in 5-mg increments or decrements within the dose range of 5 to 20 mg/day.</P>
<P>4.5 Outcomes<BR/>A variety of scales were used to assess clinical response and adverse events although trialists also reported some non-scale derived binary outcomes. Leaving the study early was well reported, as was the additional use of benzodiazepine drugs, presumably for agitation. </P>
<P>4.5.1 Outcome scales: details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are listed under "outcomes" in the "included studies" table.</P>
<P>4.5.1.1 Global functioning<BR/>Clinical Global Impression - CGI (<LINK REF="REF-Guy-1970" TYPE="REFERENCE">Guy 1970</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery.</P>
<P>4.5.1.2 Mental state<BR/>Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) <BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven-point scale varying from "not present" (1) to "extremly severe" (7). Scoring goes from 18 to 126.</P>
<P>Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>A 30-item schizophrenia scale, which is subdivided into three subscales for measuring the severity of general psychopathology, positive symptoms, and negative symptoms. Each item can be defined on a seven-point scoring system varying from absent (1) to severe (7). Scoring goes from 30 to 210. Lower scores indicate lesser severity. </P>
<P>Montgomery Asberg Depression Rating Scale - MADRS (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>)<BR/>This scale was developed using a 65-item comprehensive psychopathology scale to identify the 17 most commonly occurring symptoms in primary depressive illness. Ratings are on 10 items, with higher score indicating poor outcome. Maximum score is 30.</P>
<P>4.5.1.3 Adverse events<BR/>Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>Akathisia is a drug-induced movement disorder. The scale comprises items rating the observable, restless movements that characterise akathisia and the subjective awareness of restlessness and any distress associated with the condition. These items are rated from zero (normal) to three (severe). In addition, there is an item for rating global severity which begins at zero (absent) and increases to five (severe). A low score indicates low levels of akathisia.</P>
<P>Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>The ESRS consists of a questionnaire relating to subjective symptoms (twelve items) and to a physician´s examination for parkinsonism (18 items), for dystonia (20 items), dyskinesia (7 items) and five clinical global impressions. The subjective symptoms are rated from zero (absent) to three (severe); the examination symptoms are rated on a seven-point scoring system, the global items on a nine-point scoring system. High scores indicate severe levels of movement disorder.</P>
<P>Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This 10-item scale, with a scoring system of 0 to 4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<P>4.5.2 Missing outcomes<BR/>Because the studies were both short term we know nothing about the medium or long term term outcomes for this vulnerable group of people.</P>
<P>There are no data on important outcomes such as service utilisation outcomes (admission to the hospital, days in the hospital, change in hospital status), behaviour (compliance with treatment), social functioning, economic outcomes, quality of life and cognitive functioning in either of the included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>The two included studies were reported as randomised, but trialists did not describe the means of randomisation so studies were allocated to category 'B'.</P>
<P>2. Blinding<BR/>Both studies were double-blind, although there was no description of how blinding was assured.</P>
<P>3. Follow up<BR/>
<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> and <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> both clearly indicated the numbers of participants who left the study early and the reasons for leaving.</P>
<P>4. Overall<BR/>Both studies achieved a category B and a Jaded score of three (the top Jaded score is five). This means that the assessments for both studies show a moderate risk of bias, which raises some doubt about the results.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>The search strategy identified 1346 citations. Of these, 48 articles were ordered and inspected. We were only able to finally include twelve publications on two studies. No randomised controlled trials were identified comparing new generation antipsychotics and placebo. Nor were there randomised comparisons of one new generation antipsychotic versus another new generation antipsychotic drug.</P>
<P>2. COMPARISON 1: NEW GENERATION ANTIPSYCHOTICS versus CONVENTIONAL TREATMENT (HALOPERIDOL)</P>
<P>
<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> and <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> were the two randomised controlled trials that fulfilled the inclusion criteria.</P>
<P>3.1 Leaving the study early<BR/>Overall significantly more people who received haloperidol left the study early for any reason compared with those allocated olanzapine (n=83, 1 RCT, RR 0.43 CI 0.3 to 0.7, NNH 3 CI 2 to 8). For risperidone no significant difference between the experimental drug and haloperidol was found (n=183, 1 RCT, RR=0.7 CI 0.4 to 1.1). </P>
<P>When it came to leaving specifically because of adverse effects, the single olanzapine study found a significant difference in favour of the new drug (n=83, RR 0.1 CI 0.0 to 0.9, NNH 9 CI 4 to 89). In <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> statistically significantly fewer participants who received risperidone left the study early compared with those allocated haloperidol (n=183, RR 0.3 CI 0.1 to 0.8 NNH 8 CI 5 to 50). </P>
<P>3.2 Global state<BR/>Only <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> provided data on CGI change. No statistically significant difference was found between risperidone and haloperidol (n=183, RR not much improved 1.0 CI 0.6 to 1.5). We also considered the need of additional medication (at least one dose of benzodiazepine) as some indication of global state. Again no statistically significant difference was apparent when olanzapine was compared with haloperidol in <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> (n=83, RR needing at least one dose of benzodiazepine 0.8 CI 0.5 to 1.1).</P>
<P>3.3 Mental state<BR/>3.3.1 General binary and continuous measures<BR/>We accepted the definitions of 'clinically significant improvement' as defined by each of the studies. Sanger´s definition was a 40% or greater BPRS total improvement from baseline, Emsley defined 'clinically significant improvement' as a 50% or more reduction in total PANSS scores at endpoint. <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> and <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> usedsimilar reduction rates and rating scales (BPRS items are included in PANSS), thus their definitions were considered comparable.<BR/>
<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> found significantly more participants in the olanzapine group had clinically significant improvement compared with people allocated haloperidol (n=83, RR no 'clinically significant improvement' 0.45 CI 0.3 to 0.7, NNH 3 CI 2 to 6). In the risperidone study, however, no such difference was apparent (n=183, RR no 'clinically significant improvement' 0.85 CI 0.6 to 1.2).</P>
<P>The studies also reported several different definitions of improved/not improved.The risperidone study (<LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK>) used the number of participants with less than 50% PANSS reduction. There was no significant difference between the two treatment groups (n=183, RR 0.9 CI 0.6 to 1.2). The same trial also used a 50% cut off on the BPRS and again no statistically significant difference was apparent between risperidone and haloperidol (n=183, RR 0.8 CI 0.6 to 1.1). The olanzapine study (<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK>) had a more positive result for the new drug with significantly more people treated with haloperidol having had less than 40% reduction in the PANSS (n=83, RR 0.5 CI 0.3 to 0.7, NNT 3 CI 2 to 6).</P>
<P>Continuous measures reflected these binary findings. People treated with olanzapine had a statistically significant greater reduction in the PANSS total score than those allocated haloperidol (n=82, MD -11.2 CI -20.2 to -2.2). <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> also showed a statistically significantly higher average BPRS reduction in the olanzapine group compared to haloperidol (n=82, MD -7.8 CI -13.4 to -2.3). For risperidone, however, no significant difference was apparent between groups in terms of the change of the PANSS score from baseline to endpoint (n=182, MD -1.6 CI -8.8 to 5.6). In terms of average BPRS change, <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> also found no significant difference between groups (n=182, MD -1.1 CI -5.3 to 3.1). </P>
<P>3.3.2 Specific continuous measures<BR/>For positive symptoms, <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> found a statistically significantly higher reduction of the PANSS positive subscore in the olanzapine group (n=82, MD -3.4 CI -6.3 to -0.5). The risperidone study did not find such a difference (n=182, MD -0.1 CI -2.18 to 1.98). Only <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> provided data on the BPRS positive subscore. In terms of the mean change of BPRS positive subscore, there was no significant difference between olanzapine and haloperidol (n=82, MD -1.3 CI -3.3 to 0.7).</P>
<P>For negative symptoms, people treated with olanzapine had a borderline statistically significantly greater mean change of PANSS negative subscores than those allocated haloperidol (n=82, MD -2.7 CI -5.4 to 0.0). The risperidone study did not have clear differences between the experimental and haloperidol groups in terms of mean change of PANSS negative subscores (n=182, MD -0.5 CI 2.6 to 1.6). Only <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> provided data on the BPRS negative subscore. The mean change was statistically significantly greater in the olanzapine group compared with people getting haloperidol (n=82, MD -1.6 CI -3.1 to -0.1).</P>
<P>The olanzapine study reported specifically on depressive symptoms. <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> did not find a statistically significant difference between groups on the average change of the MADRS score (n=66, MD -2.9 CI -7.0 to 1.2).</P>
<P>3.4 Adverse events<BR/>3.4.1 General<BR/>Statistically significantly more people given haloperidol (4-16mg) experienced at least one adverse event when compared with risperidone (4-16mg) (n=183, RR 0.9 CI 0.8 to 0.98, NNH 8 CI 4 to 50). </P>
<P>3.4.2 Specific - extrapyramidal adverse events<BR/>There were many measures of extrapyramidal adverse events. Use of anticholinergic medication at least once seemed one of the most generic. Less people needed anticholinergic medication if allocated to olanzapine (n=83, RR 0.3 CI 0.2 to 0.7, NNH 4 CI 2 to 14) or risperidone (n=183, RR 0.7 CI 0.5 to 0.9, NNH 4 CI 3 to 9) compared with those given haloperidol.</P>
<P>Statistically significantly more people treated with haloperidol compared with olanzapine had a score higher than three on the Simpson-Angus-Scale (n=83, RR 0.4 CI 0.2 to 0.8, NNH 4 CI 2 to 20). <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> also reported the continuous data from this scale and a statistically significant greater average increase in the score of the Simpson-Angus-Scale in the haloperidol group compared with people taking olanzapine (n=83, MD -5.0 CI -8.1 to -1.9).</P>
<P>Significantly more people treated with haloperidol developed akathisia compared with those allocated to olanzapine (n=83, RR 0.2 CI 0.1 to 0.6, NNH 4 CI 2 to 20). <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> also reported continuous data using the Barnes Akathisia Scale. Again, people treated with olanzapine had a statistically significantly lower average increase compared with those on haloperidol (n=83, MD -0.6 CI -1.1 to -0.1).</P>
<P>The <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> study reported three other specific extrapyramidal adverse events. Extrapyramidal syndrome was not significantly more frequent for people allocated to haloperidol compared with olanzapine (n=83, RR 0.3 CI 0.1 to 1.5). However, significantly more people treated with haloperidol experienced hypertonia compared with those given olanzapine (n=83, RR 0.3 CI 0.1 to 0.8, NNH 5 CI 3 to 100). Hypokinesia was also less common in the olanzapine treated group (n=83, RR 0.1 CI 0.0 to 0.8, NNH 6 CI 3 to 100).</P>
<P>3.4.3 Specific - others <BR/>No statistically significant differences were found for any of the other adverse effects reported in the two studies. Agitation was equally common in the risperidone and haloperidol groups (n=183, RR 0.8 CI 0.3 to 1.9) as was anxiety/nervousness, in this case both for when risperidone (n=183, RR 1.0 CI 0.4 to 2.6) or olanzapine (n=83, RR 0.3 CI 0.1 to 1.5) was compared with haloperidol. <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> found no significant difference between olanzapine and haloperidol for asthenia (n=83, RR 7.9 CI 0.5 to 130.9), dizziness (n=83, RR 2.4 CI 0.3 to 19.2) or headache (n=83, RR 7.9 CI 0.5 to130.9). <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> also reported headache and again no differences were apparent between the risperidone and haloperidol groups (n=183, RR 1.1 CI 0.4 to 2.6). Finally, sleep disturbances were also equally common (about 10%) for those in the risperidone versus haloperidol study (n=183, RR insomnia 0.7 CI 0.3 to 1.4) and the olanzapine trial (n=83, RR insomnia 1.2 CI 0.4 to 4.1; n=83, RR somnolence 9.6 CI 0.6 to156.5).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. General<BR/>Although over 1300 citations were identified, it was only possible to include two studies. In these trials the new generation antipsychotics olanzapine and risperidone were compared with haloperidol. A total of 266 people is a small base upon which to judge the effects of either new drug for those with a first episode of schizophrenia or schizophrenia-like psychoses. Data on medium or long term term outcomes, service utilisation, compliance with treatment, social functioning, economic outcomes, quality of life and cognitive functioning are missing at this point. However, ten studies are still awaiting assessment and eight studies are identified as ongoing, the results of an update of this review will, hopefully, be more conclusive and comprehensive. </P>
<P>2. Concern with regard to biases<BR/>No randomised controlled trials were identified comparing new generation antipsychotics with placebo. As it is acknowledged that new generation antipsychotics are more effective than placebo for people whohave had multiple-episodes of schizophrenia, placebo controlled studies would be difficult, and perhaps unethical to undertake - although the latter may be debatable considering the poor state of knowledge for some of these compounds (<LINK REF="REF-Duggan-2003" TYPE="REFERENCE">Duggan 2003</LINK>). </P>
<P>More concerning is that we found no comparisons of new generation antipsychotics versus similar new generation drugs and that only one of the eight ongoing studies (<LINK REF="STD-Kane-2001" TYPE="STUDY">Kane 2001</LINK>) is investigating this comparison (olanzapine versus risperidone versus ziprasidone). Haloperidol is an effective antipsychotic but with a considerable adverse effect profile (<LINK REF="REF-Joy-2003" TYPE="REFERENCE">Joy 2003</LINK>). Haloperidol is not recommended any more as the first choice drug for starting people on with their first episode of schizophrenia (<LINK REF="REF-Marder-2002" TYPE="REFERENCE">Marder 2002</LINK>). In many of the countries where atypicals are now available, haloperidol would not be used as a first choice, yet in these ongoing studies it has been chosen as the control drug. However, three of the ongoing studies (<LINK REF="STD-Schooler-1997a" TYPE="STUDY">Schooler 1997a</LINK>, <LINK REF="STD-M_x00f6_ller-2000" TYPE="STUDY">Möller 2000</LINK>, <LINK REF="STD-Gaebel-2000" TYPE="STUDY">Gaebel 2000</LINK>) are using lower doses of haloperidol (<LINK REF="STD-Schooler-1997a" TYPE="STUDY">Schooler 1997a</LINK> 1-4 mg per day) as comparator drugs. More informative and interesting comparators would be low dose chlorpromazine (<LINK REF="REF-Thornley-2003" TYPE="REFERENCE">Thornley 2003</LINK>) or sulpride (<LINK REF="REF-Soares-2000" TYPE="REFERENCE">Soares 2000</LINK>). </P>
<P>
<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> is a sub-group analysis of <LINK REF="REF-Tollefson-1997" TYPE="REFERENCE">Tollefson 1997</LINK>. The larger <LINK REF="REF-Tollefson-1997" TYPE="REFERENCE">Tollefson 1997</LINK> is one of the most reported and analysed datasets in psychiatry (<LINK REF="REF-Duggan-2003" TYPE="REFERENCE">Duggan 2003</LINK>) and sub-group analyses are notorious for dredging up spurious significant associations (<LINK REF="REF-ISIS_x002d_2-1988" TYPE="REFERENCE">ISIS-2 1988</LINK>).<BR/>All results of this review must be treated with caution. </P>
<P>3. Comparison 2. New generation antipsychotics versus conventional treatment<BR/>3.1 Leaving the study early<BR/>Significantly more participants receiving conventional treatment with haloperidol left the study early in the <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> study. This can be interpreted as indicating a better acceptability of treatment in favour of olanzapine. However, the mean haloperidol dose was rather high (10.8 mg/day) and this might have accounted in part for this difference. <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> observed no such superiority in the risperidone study. Here the mean haloperidol dose was much lower (5.6 mg/day).</P>
<P>3.2 Global state<BR/>Neither study shows the new drugs to be superior to haloperidol in terms of 'no clinically significant global change'. All data are, however, short term, and from small studies. More data, perhaps from the assimilated awaited or ongoing studies, may be more informative. </P>
<P>3.3 Mental state<BR/>All outcomes in the small (n=83) sub-group analysis, except for depression and mean change of BPRS positive subscore, were significantly in favour of olanzapine (<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK>). The clinical meaning of the results of the continuous measures is unclear. </P>
<P>A number needed to treat (NNT) of three in regard to 40% PANSS reduction suggests a rather strong effect, perhaps too strong for the clinical reality. Original studies using lower haloperidol doses are required to confirm this finding. More studies are also needed to investigate whether any real effect in favour of risperidone exists, as the findings of <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> suggest that it may, but includes such wide confidence intervals that considerable doubt remains.</P>
<P>3.4 Adverse events<BR/>In both studies, significantly more participants treated with haloperidol left the study early due to adverse events. Treating people with a first episode of schizophrenia with new generation antipsychotics might be presumed to cause fewer adverse events in general in the first six weeks of treatment and in <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> significantly more participants treated with haloperidol had at least one adverse event. (n=183, RR 0.9 CI 0.8 to 0.98, NNH 8 CI 4 to 50). Perhaps what is interesting here is that the difference is not greater. Adverse effects of haloperidol, even at the lower doses used in this study, are common and noticeable (<LINK REF="REF-Joy-2003" TYPE="REFERENCE">Joy 2003</LINK>, <LINK REF="REF-Waraich-2003" TYPE="REFERENCE">Waraich 2003</LINK>). Treating eight people with an expensive drug in order to avoid one or more of the common adverse effects of haloperidol may not seem so attractive when data from some older inexpensive drugs could be used to make similar claims. </P>
<P>
<LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> reported movement disorder adverse effects (favouring olanzapine compared with ~11 mg haloperidol) and so did <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> (favouring risperidone versus ~6 mg haloperidol), but Emsley´s ESRS data were not usable for this review due to missing standard deviation. Movement disorders are common with even low doses of haloperidol (<LINK REF="REF-Waraich-2003" TYPE="REFERENCE">Waraich 2003</LINK>) so it is not surprising that in both studies people treated with haloperidol needed more anticholinergic medication. Compared with an average of 11 mg of haloperidol olanzapine was superior for a range of extrapyramidal symptoms. Fewer extrapyramidal adverse events in the first weeks of treatment might be of substantial importance for long-term compliance for people with first episode schizophrenia (<LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>). </P>
<P>Interestingly and surprisingly, other adverse events, such as asthenia, dizziness and somnolence, showed no difference between new and conventional antipsychotic medication. It was not possible to analyse weight gain in this review, although it is known to be a problem with olanzapine and risperidone (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>). <LINK REF="STD-Sanger-1999" TYPE="STUDY">Sanger 1999</LINK> reported weight gain, but data were incomplete for the use in this review. <LINK REF="STD-Emsley-1999" TYPE="STUDY">Emsley 1999</LINK> did not report on weight gain.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with a first episode of schizophrenia<BR/>People with a first episode of schizophrenia or schizophrenia-like psychoses may want to know if these drugs are more effective for treating the symptoms of schizophrenia than older drugs. This review suggests that they may be as effective as haloperidol, but even for this outcome more data are needed. Besides movement disorders, weight gain is of concern for people with schizophrenia (<LINK REF="REF-Allison-2001" TYPE="REFERENCE">Allison 2001</LINK>). People with a first episode of schizophrenia or their immediate carers, may also be interested to know that the research community has not, as yet, produced informative data on which new compound is best for their situation. </P>
<P>2. For clinicians<BR/>Based on currently available randomised trial-derived evidence, data are too limited to assess whether new generation antipsychotics are particularly beneficial for people with a first episode schizophrenia or schizophrenia-like psychoses. For example, it is often stated that the treatment with new generation antipsychotics improves long-term compliance, yet no relevant long-term data are available. In the absence of such data, the choice of treatment must therefore be based on similar principles as for people who have already had several episodes. More data will become available in the next few years but the choice of comparison drug (mainly haloperidol) in these ongoing studies makes it questionable whether the results will greatly change. </P>
<P>3. For managers and policy makers<BR/>Managers and policy makers should be aware that the notion that new generation antipsychotics are particularly beneficial for those with a first episode of schizophrenia is not based on evidence derived from randomised controlled trials. Whether new drugs induce fewer extrapyramidal adverse effects leading to better compliance and lower rehospitalisation and costs is, as yet, unproven. However, further trials are underway which might elucidate this issue.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>Any future studies should respect standards of measuring outcomes and of reporting data in order to enhance the comparability of study results (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). </P>
<P>2. Specific<BR/>More relevant studies are needed. At least some of these should be independent of industry as these carry substantial biases (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>, <LINK REF="REF-Healy-2003" TYPE="REFERENCE">Healy 2003</LINK>). The control older generation drug should not be haloperidol and more new generation versus new generation comparisons are necessary. Well-designed, large, long term, fully reported pragmatic trials with clinically relevant outcomes such as relapse and rehospitalisation are essential but completely lacking at this point.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to thank the editorial base of the CSG for their continuous help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>CR received lecture honoraria and/or travel grants to attend scientific meetings from Janssen-Cilag, Eli Lilly and Pfizer. SL and WK received lecture honoraria and/or travel grants to attend scientific meetings from Janssen-Cilag, Eli Lilly, Lundbeck, Pfizer, Sanofi-Synthlabo and Zeneca. They also received financial support for a randomised trial from Eli Lilly, and for a meta-analysis on amisulpride from Sanofi-Synthelabo. WK received lecture honoraria form Novartis and BMS. JH received financial support to attend a scientific meeting from Janssen- Cilag. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Christine Rummel - protocol development, searching, data extraction, analysis, data interpretation and writing the final report.</P>
<P>Johannes Hamann - protocol development, data extraction, data checking, data interpretation.</P>
<P>Werner Kissling - protocol development, data interpretation.</P>
<P>Stefan Leucht - protocol development, searching, data extraction, data checking, data interpretation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-1999" NAME="Emsley 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emsley R, McCreadie R, Livingston M, De Smedt G, Lemmens P</AU>
<TI>Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study</TI>
<SO>8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emsley R, McCreadie R, Livingston M, De Smedt G, Lemmens P</AU>
<TI>Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double-blind study</TI>
<SO>Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emsley RA</AU>
<TI>Risperidone in the treatment of first episode psychotic patients: a double-blind multicenter study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>4</NO>
<PG>721-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanger-1999" NAME="Sanger 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C Jr, Tollefson G</AU>
<TI>Olanzapine versus haloperidol treatment in first episode psychosis</TI>
<SO>11th Congress of the European College of Neuropsychopharmacology; 1998 Oct 31 - Nov 4, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Lieberman JA, Tohen M, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol in the treatment of first episode psychosis</TI>
<SO>21st Congress of the Collegium Internationale Neuro-pssychopharmacologicum; 1998 July 12-16, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Lieberman JA, Tohen M, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol in the treatment of psychosis</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - June 4, Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Tollefson GD, Lieberman JA, Tohen M</AU>
<TI>Olanzapine versus haloperidol in the treatment of first-episode psychosis</TI>
<SO>150th Annual Meeting of the American Psychiatric Assiciation; 1997 May 17-22, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol treatment in first-episode psychosis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>1</NO>
<PG>79-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanger TM, Lieberman JA, Tohen M, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol in the treatment of first episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>151</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999107319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tohen M, Sanger T, Tollefson GD</AU>
<TI>Gender differences in the response of olanzapine versus haloperidol in the treatment of first-episode psychosis</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM, Lieberman JA</AU>
<TI>Olanzapine versus haloperidol in the treatment of first episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1+2</NO>
<PG>193</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-2000" NAME="Breier 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Breier A, Wright P, Birkett M, Meehan K, David S, Brook S</AU>
<TI>A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellva-1998" NAME="Dellva 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Dellva MA, Beasley CM, Kuntz AJ, Tamura RN, Glazer WM, Morgenstern H, Tollefson GM</AU>
<TI>What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?</TI>
<SO>11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 March 8-11, San Diego, USA</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denney-2001" NAME="Denney 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Denney D, Stevens JR, Wilson WH, Ward M</AU>
<TI>Low dose clozapine treatment of drug resistant schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>225</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-1997" NAME="Ferrari 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari MCL, Elkis H</AU>
<TI>A six month trial of risperidone versus conventional neuroleptics in young patients with early onset schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1+2</NO>
<PG>194</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-2000" NAME="Fischer 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fischer W, Riedel M, Müller N, Möller HJ</AU>
<TI>Primary negative symptom schizophrenia: a study with the atypical neuroleptic zotepine</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutierrez-1996" NAME="Gutierrez 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Gutierrez R</AU>
<TI>The long term value of an SDA in schizophrenia</TI>
<SO>10th World Congress of Psychiatry; 1996 August 23-28, Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haffmans-1996" NAME="Haffmans 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Haffmans P, Oolders J, von Bargen B, Hoencamp E</AU>
<TI>Subjective and objective sleep in schizophrenia</TI>
<SO>8th Congress of the Association of European Psychiatrists; 1996 July 7-12, London, UK</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-2000" NAME="Hamilton 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton SH, Edgell ET, Revicki DA, Breier A</AU>
<TI>Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>245-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalali-2000" NAME="Kalali 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Kalali A, Lasser R, Campbell B, Cucchiaro J, El-Mizri H, Guven A, Matkovits-Gupta T, Nann-Vernotica E, Narurkar M, Pirozzi C, Gharabawi G</AU>
<TI>The management of cultural differences and the importance of safety monitoring in global studies: the realize clinical program</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenny-1992" NAME="Kenny 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Kenny JT, Meltzer HY</AU>
<TI>Effect of atypical and typical antipsychotic drugs on neuropsychological functions in early-stage schizophrenic patients</TI>
<SO>7th Biennial European Winter Workshop on Schizophrenia; 1994 Jan 23-28, Les Diablerets, Switzerland</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>2</NO>
<PG>162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keshavan-1998" NAME="Keshavan 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keshavan MS, Schooler NR, Sweeney JA, Haas GL, Pettegrew JW</AU>
<TI>Research and treatment strategies in first episode psychoses: the Pittsburgh experience</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>172</VL>
<NO>33 Suppl</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-1999" NAME="Kinon 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Kinon B, Basson BR, Malcolm SK, Tollefson G</AU>
<TI>Strategies for switching from conventional antipsychotic drugs to olanzapine</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20th, Washington, USA</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2001" NAME="Kinon 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Gilmore J, Wang L</AU>
<TI>Exploration of a dose-response relationship in schizophrenia with the novel antipsychotic drug olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>234-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Gilmore JA, Gottschalk LA</AU>
<TI>Exploration of a dose-response relationship in schizophrenia with the novel antipsychotic drug olanzapine</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lam-2001" NAME="Lam 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lam YW, Ereshefsky L, Toney GB, Gonzales C</AU>
<TI>Branded versus generic clozapine: bioavailability comparison and interchangeability issues</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>Suppl 5</NO>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1999" NAME="Lee 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee MA, Jayathilake K, Meltzer HY</AU>
<TI>A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic responsive schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer-2001" NAME="Lemmer 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Lemmer W, Lehmann E</AU>
<TI>The efficacy and tolerance of zotepine and haloperidol in acute schizophrenia and the differential therapy of kava-kava</TI>
<SO>7th World Congress of Biological Psychiatry. 2001 July 1-6, Berlin, Germany</SO>
<YR>2001</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magnuson-2001" NAME="Magnuson 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Magnuson WG</AU>
<TI>Childhood onset psychotic disorders: characterization and treatment with atypical neuroleptics. Treatment of childhood onset psychotic disorders with olanzapine or clozapine</TI>
<SO>National Institutes of Health</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-1998" NAME="Mahmoud 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Mahmoud RA, Engelhart LM, Oster G, Ollendorf DAU</AU>
<TI>Psychiatric resource use under usual care conditions - does risperidone increase resource use?</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - June 4, Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malla-2001" NAME="Malla 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malla AK, Norman RM, Scholten DJ, Zirul S, Kotteda V</AU>
<TI>A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>3</NO>
<PG>179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGlashan-1999" NAME="McGlashan 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGlashan TH</AU>
<TI>Treatment intervention in the New Haven prime clinic prodromal sample</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>s62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGorry-1999" NAME="McGorry 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGorry P, Adlard S, Yung A, McDonald A, Phillips L, Hearn N</AU>
<TI>Detection and intervention in pre-psychotic schizophrenia</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>s62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2000" NAME="Meltzer 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer H, Arato M, O´Connor R</AU>
<TI>Path analysis of the Zeus study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>208-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merlo-2000" NAME="Merlo 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Merlo MCG, Hofer H, Marder SR</AU>
<TI>Effects on clinical psychopahrmacology and fine motor functions of 2 versus 4 mg risperidone in first episode psychotic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mockler-1999" NAME="Mockler 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mockler DM, O´Neill ST, Soni W, Morris RG, Sharma T</AU>
<TI>The effects of risperidone and typical antipsychotic drug treatments on memory function in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2 &amp; 3</VL>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdon-2000" NAME="Purdon 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>David SR, Purdon S, Jones BD, Stip E, Labelle A, Breier AF, Tollefson GD, Kutcher SP, MacLaren C, Hadrava V, Thompson PM, Leblanc</AU>
<TI>Olanzapine versus risperidone versus haloperidol in early illness schizophrenia</TI>
<SO>152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20th, Washington, USA</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Jones B, Labelle A, Addington D, Tollefson G</AU>
<TI>A mulitcentre comparison of olanzapine, risperidone and haloperidol on working memory, new learning and delayed recall of verbal and nonverbal materials in early-phase schizophrenia over a 12-month prospective double-blind clinical trial</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2 &amp; 3</VL>
<PG>150</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD</AU>
<TI>Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>3</NO>
<PG>249-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, Breier A, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol versus risperidone in early illness schizophrenia</TI>
<SO>Unpublished data on file</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramaekers-1999" NAME="Ramaekers 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de-Bie A, Rosenzweig P, Patat A, O´Hanlon JF</AU>
<TI>Psychomotor, cognitive, extrapyramidal and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>3</NO>
<PG>209-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rein-1997" NAME="Rein 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rein W, Turjanski S</AU>
<TI>Clinical update on amisulpride in deficit schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>Suppl 2</NO>
<PG>s19-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2000" NAME="Robinson 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson G, Wheeler A, Byrd J, Visser S</AU>
<TI>Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>s291</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanger-1997" NAME="Sanger 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Tollefson GD</AU>
<TI>A controlled study on the course of primary and secondary negative symptoms</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-1997" NAME="Schooler 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schooler N, Borenstein M, Ames D, Baker R, Umbricht D, Wirshing W, Kane J, Marder S</AU>
<TI>First improvement with clozapine: How patient should we be?</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1+2</NO>
<PG>188</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-2000" NAME="Schooler 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR</AU>
<TI>Ziprasidone´s effect on anxiety in a group of outpatients with stable schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz--1997" NAME="Schulz  1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schulz E, Fleischhaker C, Clement HW, Remschmidt H</AU>
<TI>Blood biogenic amines during clozapine treatment of early onset schizophrenia</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>10</NO>
<PG>1077-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz E, Fleischhaker C, Remschmidt H</AU>
<TI>Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>2</NO>
<PG>119-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2000" NAME="Singh 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Singh V</AU>
<TI>A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg/day versus olanzapine 5 to 20 mg/day in patients with schizophrenic disorders</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1998" NAME="Smith 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Smith RC, Nigam S, Stern A, Infante M, Mehta R</AU>
<TI>Olanzapine in chronic nonresponding schizophrenia: effects on psychopathology and neurocognitive function</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 July 12-16, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swift-1998" NAME="Swift 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Swift RH, Harrigan EP, Kammen DP</AU>
<TI>A comparison of intramuscular (im) ziprasidone with im haloperidol</TI>
<SO>9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24, Copenhagen, Denmark</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szulecka-2000" NAME="Szulecka 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Szulecka K</AU>
<TI>Open label extension of treatment with seroquel for patients who have participated in the phase IIIb clinical trial programme of project 321 multicentre double blind randomised comparison of seroquel &amp; amp; risperidone</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamminga-1994" NAME="Tamminga 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM</AU>
<TI>Clozapine in tardive dyskinesia: observations from human and animal model studies</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>Suppl B</NO>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-2000" NAME="Wright 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wright P, Birkett M, Ferchland I, David S, Alaka K, Pullen P, Brook S, Reinstein M, Breier A</AU>
<TI>A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>s304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1999" NAME="Edwards 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Edwards J, Maude D, McGorry P, Cocks J, Burnett P, Davern M, Bennett C, Harrigan S, Herman T, Wade D, Bell R</AU>
<TI>Treatment of enduring positive symptoms in first-episode psychosis: a randomised controlled trial of cbt and clozapine</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2 &amp; 3</VL>
<PG>278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glenthoj-2001" NAME="Glenthoj 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen R</AU>
<TI>Effects of antipsychotics on information-processing and extrastriatal dopamine d2/d3 receptors in first-episode drug-naive schizophrenic patients</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen RP</AU>
<TI>Effects of antipsychotic treatment on prepulse inhibition of the startle response (ppi) and cognition in first episode drug-naive schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1994" NAME="Gordon 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon C, Frazier J, McKenna K, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus K, Rapoport J</AU>
<TI>Childhood-onset schizophrenia: a NIMH study in progress</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>4</NO>
<PG>697-712</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarboe-2001" NAME="Jarboe 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarboe KS, Lewine RR</AU>
<TI>Haloperidol versus olanzapine induced weight gain and clinical relevance, a double-blind and open label comparison</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keefe-2001" NAME="Keefe 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keefe RS, Seiden LJ, Christensen B, Yurgelun-Todd DA, Lewine RR, Sitskoorn M, Sharma T, Clark WS, Sanger TM, Tohen M, Lieberman JA</AU>
<TI>Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14, San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RS, Seidman LJ, Christensen BK, Yurgelun-Todd DA, Lewine RR, Lieberman MM, Sitskoorn J</AU>
<TI>Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumra-1996" NAME="Kumra 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus KE</AU>
<TI>Childhood-onset schizophrenia: an NIMH study in progress</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>4</NO>
<PG>697-712</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95215796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband Rad J, Rapoport JL</AU>
<TI>Childhood-onset schizophrenia. A double-blind clozapine-haloperdol comparison</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>12</NO>
<PG>1090-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97115273"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavalaye-1999" NAME="Lavalaye 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van-Royen EA</AU>
<TI>Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia</TI>
<SO>Psychiatry Research</SO>
<YR>1999</YR>
<VL>92</VL>
<NO>1</NO>
<PG>33-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2000" NAME="Lieberman 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green A, Tohen M, Strakowski SM, Lieberman JA, Glick D, Clarke SW</AU>
<TI>Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>230</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2001-14228-005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Lieberman J, Tohen M, McEvoy J, Sanger T, Keefe R, Charles C, Clark S, Brier A, Tollefson G</AU>
<TI>Olanzapine versus haloperidol in the treatment of first episode psychosis</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2001" NAME="Lieberman 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Phillips M, Kong L, Gu H, Koch G</AU>
<TI>Efficacy and safety of clozapine versus chlorpromazine in first episode psychosis: results of a 52-week randomized double-blind trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>236</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman JA, Phillips M, Kong L, Gu H, Koch G</AU>
<TI>Efficacy and safety of clozapine versus chlorpromazine in first-episode psychosis: results of a 52 week randomized double-blind trial</TI>
<SO>39th Annual Meeting og the American College of Neuropsychopharmacology 2000; Dec 10 - 14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Bruggen-1999" NAME="van Bruggen 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Bruggen JM, Linszen DH, Dingemans PM</AU>
<TI>An open study of olanzapine versus riperidone in the management of early-phase schizophrenia and related disorders</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2 &amp; 3</VL>
<PG>316-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gaebel-2000" NAME="Gaebel 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Gaebel W</AU>
<TI>Pharmacological long-term treatment strategies for relapse prevention in first episode schizophrenia</TI>
<SO>N/A</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2001" NAME="Kane 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Kane JM</AU>
<TI>Preventing morbidity in first-episode schizophrenia</TI>
<SO>National Institutes of Health</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-M_x00f6_ller-2000" NAME="Möller 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Möller HJ</AU>
<TI>Optimization of acute treatment in first episode schizophrenic patients by new pharmacological treatments</TI>
<SO>N/A</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reveley-2000" NAME="Reveley 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen M</AU>
<TI>The impact on long-term outcome of early intervention with risperidone or haloperidol in first episode psychosis: characteristics at baseline</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2 &amp; 3</VL>
<PG>293</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20473833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Reveley M</AU>
<TI>Ris-int-35 a double blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosebush-2000" NAME="Rosebush 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Rosebush P, Mazurek M</AU>
<TI>Olanzapine versus haloperidol in randomized trials of first-episode patients with schizophrenia</TI>
<SO>Stanley Foundation Research Awards - 2000 Research Award Recipients</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-1997a" NAME="Schooler 1997a" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Smedt G</AU>
<TI>Risperidone versus haloperidol in first episode psychosis</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11, Hamburg, Germany</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rasmussen M</AU>
<TI>The impact on long term outcome of early intervention with risperidone or haloperidol in first episode psychosis: characteristics at baseline</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 July 12-16, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Schooler NR</AU>
<TI>The FutuRIS study - a prospective long-term evaluation of risperidone versus haloperidol in early psychosis patients</TI>
<SO>6th World Congress of Biological Psychiatry; 1997 June 22-27, Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2000" NAME="Sharma 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Sharma T</AU>
<TI>A double-blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2000a" NAME="Sharma 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Sharma T</AU>
<TI>The acute and long-term efficacy of olanzapine in first-episode psychotic disorders: a randomised double-blind comparison with haloperidol</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Allison-1999" NAME="Allison 1999" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ Antipsychotic-induced weight gain: a comprehensive research synthesis.</AU>
<TI>Antipsychotic-induced weight gain: a comprehensive research synthesis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>11</NO>
<PG>1686-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allison-2001" NAME="Allison 2001" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Casey DE</AU>
<TI>Antipsychotic-induced weight gain: a review of the literature</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62 Suppl 7</VL>
<PG>22-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagnall-2002" MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]" NAME="Bagnall 2002" TYPE="COCHRANE_REVIEW">
<AU>Bagnall A-M, Fenton M, Lewis R, Leitner ML, Kleijnen J</AU>
<TI>Molindone for schizophrenia and severe mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:36:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002083.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TRE</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bottlender-2003" NAME="Bottlender 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bottlender R, Sato T, Jager M, Wegener U, Wittmann J, Strauss A, Moller HJ</AU>
<TI>The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia</TI>
<SO>Schizophr Res</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>1-2</NO>
<PG>37-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G</AU>
<TI>Extrapyramidal Symptom Rating Scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2008-11-05 08:31:59 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD</AU>
<TI>Cochrane reviewers' handbook</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtis-1995" NAME="Curtis 1995" TYPE="JOURNAL_ARTICLE">
<AU>Curtis VA, Kerwin RW</AU>
<TI>A risk-benefit assessment of risperidone in schizophrenia</TI>
<SO>Drug Saf</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>2</NO>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium</SO>
<YR>2000</YR>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2003" MODIFIED="2008-11-05 08:33:27 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 2003" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:33:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:33:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenton-2002" MODIFIED="2008-11-05 08:32:58 +0000" MODIFIED_BY="[Empty name]" NAME="Fenton 2002" TYPE="COCHRANE_REVIEW">
<AU>Fenton M, Murphy B, Wood J, Bagnall A-M, Chue P, Leitner M</AU>
<TI>Loxapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:32:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:32:58 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001943.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleischhacker-2001" NAME="Fleischhacker 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Lemmens P, van Baelen B</AU>
<TI>A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a ripseridone database</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>3</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gattaz-1994" NAME="Gattaz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gattaz WF, Schummer B, Behrens S</AU>
<TI>Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats</TI>
<SO>J Neural Transm Gen Sect</SO>
<YR>1994</YR>
<VL>96</VL>
<NO>3</NO>
<PG>227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1970" NAME="Guy 1970" TYPE="BOOK_SECTION">
<AU>Guy W, Bonato RR</AU>
<TI>Clinical Global Impressions</TI>
<SO>Manual for the ECDEU Assessment Battery</SO>
<YR>1970</YR>
<EN>2nd</EN>
<ED>Guy W, Bonato RR</ED>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Healy-2003" NAME="Healy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Interface between authorship, industry and science in the domain of therapeutics</AU>
<TI>Healy D, Cattell D</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>183</VL>
<PG>22-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herz-2000" NAME="Herz 2000" TYPE="BOOK_SECTION">
<AU>Herz MI, Liberman RP, Marder SR, McGlashan TH, Wyatt RJ, Wang P</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia</TI>
<SO>Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2000</SO>
<YR>2000</YR>
<PG>299-412</PG>
<PB>American Psychiatric Association</PB>
<CY>Washington D.C.</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISIS_x002d_2-1988" NAME="ISIS-2 1988" TYPE="JOURNAL_ARTICLE">
<AU>Second International Study of Infarct Survival Collaborative Group</AU>
<TI>Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>2</VL>
<PG>349-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joy-2003" MODIFIED="2008-11-05 08:34:48 +0000" MODIFIED_BY="[Empty name]" NAME="Joy 2003" TYPE="COCHRANE_REVIEW">
<AU>Joy CB, Adams CE, Lawrie SM</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:34:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:34:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>261-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marder-2002" NAME="Marder 2002" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR</AU>
<TI>The Mount Sinai conference on the pharmacotherapy of schizophrenia</TI>
<SO>Schizophr Bull</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>1</NO>
<PG>5-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-1999" NAME="McEvoy 1999" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Schaffler PL, Frances A</AU>
<TI>Treatment of schizophrenia 1999. The expert consensus guideline series</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60 (suppl 11)</VL>
<PG>3-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1994" NAME="Meltzer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>An overview of the mechanism of action of clozapine</TI>
<SO>J Clin Psychiatry</SO>
<YR>1994</YR>
<VL>55 Suppl B</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, CONSORT Group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>2001</SO>
<YR>JAMA</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2002" NAME="NICE 2002" TYPE="OTHER">
<AU>National Institute for Clinical Excellence (NICE)</AU>
<TI>Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia</TI>
<SO>NICE Technology Appraisal No. 43</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oehl-2000" NAME="Oehl 2000" TYPE="JOURNAL_ARTICLE">
<AU>Oehl M, Hummer M, Fleischhacker WW</AU>
<TI>Compliance with antipsychotic treatment</TI>
<SO>Acta Psychiatr Scand Suppl</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>407</NO>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perrault-1997" NAME="Perrault 1997" TYPE="JOURNAL_ARTICLE">
<AU>Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B</AU>
<TI>Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1997</YR>
<VL>280</VL>
<NO>1</NO>
<PG>73-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1997" NAME="Reynolds 1997" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds GP</AU>
<TI>What is an atypical antipsychotic</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>195-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA</AU>
<TI>Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>2-3</NO>
<PG>209-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scatton-1997" NAME="Scatton 1997" TYPE="JOURNAL_ARTICLE">
<AU>Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H</AU>
<TI>Amisulpride: from animal pharmacology to therapeutic action</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12 (suppl)</VL>
<PG>S29-S36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schotte-1996" NAME="Schotte 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE</AU>
<TI>Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding</TI>
<SO>Psychopharmacology</SO>
<YR>1996</YR>
<VL>124</VL>
<NO>1-2</NO>
<PG>57-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson M, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soares-2000" MODIFIED="2008-11-05 08:34:02 +0000" MODIFIED_BY="[Empty name]" NAME="Soares 2000" TYPE="COCHRANE_REVIEW">
<AU>Soares BG, Fenton M, Chue P</AU>
<TI>Sulpiride for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:34:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:34:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thornley-2003" MODIFIED="2008-11-05 08:35:46 +0000" MODIFIED_BY="[Empty name]" NAME="Thornley 2003" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Rathbone J, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:35:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:35:46 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tollefson-1997" NAME="Tollefson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME</AU>
<TI>Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Waraich-2003" MODIFIED="2008-11-05 08:35:12 +0000" MODIFIED_BY="[Empty name]" NAME="Waraich 2003" TYPE="COCHRANE_REVIEW">
<AU>Waraich PS, Adams CE, Roque M, Hamill KM, Marti J</AU>
<TI>Haloperidol dose for the acute phase of schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 08:35:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 08:35:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001951"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Emsley-1999">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details.<BR/>Duration: 6 weeks.<BR/>Multi-centre, multi-national.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: provisional schizophreniform disorder or schizophrenia (DSM-III-R).<BR/>Age: median ~25 years.<BR/>N=183.<BR/>Age at onset of first symptoms of psychosis: median ~ 24 years.<BR/>Sex: female 61, male 122.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone 4-16 mg/d. N=99.<BR/>2. Haloperidol 4-16 mg/d. N=84.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Clinical response: 50% reduction in PANSS or BPRS PANSS-derived.<BR/>Global state: CGI.<BR/>Mental state: BPRS PANSS-derived, PANSS.</P>
<P>Unable to use - <BR/>Global state: GAF (no endpoint data).<BR/>Extrapyramidal adverse effects: ESRS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanger-1999">
<CHAR_METHODS>
<P>Allocation: random - in a 2:1 (olanzapine:haloperidol) ratio.<BR/>Blinding: double - no further details.<BR/>Duration: 6 weeks (preceeded by 2-9 days screening and washout).<BR/>Multi-centre, multi-national.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, schizophreniform disorder or schizoaffective disorder<BR/>(DSM-III-R), BPRS score at least 18.<BR/>N=83.<BR/>Age: mean ~ 28 years.<BR/>Age at onset of current episode: ~ 27 years.<BR/>Sex: female 26, male 57.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine 5-20 mg/d. N=59.<BR/>2. Haloperidol 5-20 mg/d. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Clinical response: 40% BPRS improvement.<BR/>Mental state: BPRS - PANSS derived, MADRS, PANSS.<BR/>Extrapyramidal adverse effects: Barnes Akathisia Scale, Simpson-Angus Scale.</P>
<P>Unable to use - <BR/>Weight gain (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General abbreviations:<BR/>SD - Standard Deviation</P>
<P>Diagnostic tools:<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, third edition, revised.</P>
<P>Global effect scales:<BR/>CGI - Clinical Global Impression<BR/>GAF - Global Assessment of Functioning</P>
<P>Mental state scales:<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>PANSS - Positive and Negative Symptom Scale<BR/>MADRS - Montgomery-Asberg Depression Rating Scale</P>
<P>Side effect scales:<BR/>ESRS - Extrapyramidal Symptom Rating Scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Breier-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: acutely agitated schizophrenic people, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dellva-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details .<BR/>Participants: people with a diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denney-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: chronically ill schizophrenic people, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferrari-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a diagnosis of schizophrenia (DSM-III-R), no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fischer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: people with a diagnosis of chronic residual schizophrenia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gutierrez-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with chronic schizophrenia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haffmans-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: clinically stable schizophrenic outpatients wtihout acute psychotic symptoms, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamilton-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalali-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with psychotic disorders, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kenny-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: treatment resistant schizophrenic people, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keshavan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: outpatients with a diagnosis of schizophrenia or schizoaffective disorder who were clinically stable, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: schizophrenic people, probably not those with first episode schizophrenia .<BR/>Interventions: olanzapine 5mg/d vs 10mg/d vs 15 mg/d.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lam-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: schizophrenic people, probably not those with first episode schizophrenia.<BR/>Interventions: generic clozapine vs Clozaril.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with recent onset, neuroleptic-responsive schizophrenia or schizoaffective disorder, not those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lemmer-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with acute paranoid halluzinatory schizophrenia, no first episode schizophrenic persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magnuson-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: children and adolescents with psychotic conditions (schizophrenia, schizoaffective disorder, psychotic disorder not otherwise specified), no first episode schizophrenic patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmoud-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: schizophrenic people during relapse relapse, not clearly people in their first episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malla-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: matched, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGlashan-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with prodromal, prepsychotic symptoms, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGorry-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: young people wtih an "at risk mental state", no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meltzer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with chronic, stable schizophrenia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merlo-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a first episode of schizophrenia, schizophreniform or schizoaffective disorder.<BR/>Interventions: risperidone 2 mg vs risperidone 4 mg.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mockler-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: schizophrenic people and healthy volunteers, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Purdon-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a diagnosis of schizophrenia who were within 5 years of their first exposure to neuroleptic medication, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramaekers-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rein-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: people with predominantly negative deficit symptoms of schizophrenia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with stable schizophrenia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanger-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: schizophrenic people, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schooler-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: schizophrenic people, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schooler-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised to one of three dosing schedules.<BR/>Participants: outpatients with stable schizophrenia, no first episode schizophrenic persons.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schulz--1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: young people with a diagnosis of chronic schizophrenia (80%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a diagnosis of schizophrenia or schizophreniform disorder, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: chronically hospitalized schizophrenic people, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Swift-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with psychotic disorder, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Szulecka-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with acute exacerbation of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tamminga-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: schizophrenic people with tardive dyskinesia, no people with a first episode of schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wright-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: acutely agitated people with schizophrenia, not specifically those with first episode schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Edwards-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Glenthoj-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gordon-1994">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Jarboe-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Keefe-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kumra-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lavalaye-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lieberman-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lieberman-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-van-Bruggen-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Gaebel-2000">
<CHAR_STUDY_NAME>
<P>Pharmacological long-term treatment strategies for relapse prevention in first episode schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>First treatment year: 140 patients with first episode in schizophrenia.<BR/>Second treatment year: 71 patients with first episode in schizophrenia after one year under maintenance neuroleptic treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>First treatment year: <BR/>1. Risperidone.<BR/>2. Haloperidol. Second treatment year: <BR/>1. Maintenance Treatment.<BR/>2. Drug discontinuation. Each with prodrome based early intervention.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Relapse.<BR/>Rehospitalisation.<BR/>Psychopathology (HAMD, CDSS, PANSS, SANS, CGI, YMRS).<BR/>Adverse events (AIMS, EPS, HAS, UKU).<BR/>Social functioning.<BR/>Quality of life (LQLP).<BR/>Neurocognitive funtioning.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>December 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. Dr. W. Gaebel, Department of Psychiatry, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstr. 2, 40629 Düsseldorf, Germany.<BR/>wolfgang.gaebel@uni-duesseldorf.de</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Kane-2001">
<CHAR_STUDY_NAME>
<P>Preventing morbidity in first-episode schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with a first episode of schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine.<BR/>2. Risperidone.<BR/>3. Ziprasidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Psychopathology (positive, negative and affective symptoms). <BR/>Side effects.<BR/>Neurocognition (executive function, memory, attention).<BR/>Social and occupational function.<BR/>Service utilization.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>John M. Kane, MD, 75-29 263rd St., Glen Oaks, New York, 11004, United States.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-M_x00f6_ller-2000">
<CHAR_STUDY_NAME>
<P>Optimization of acute treatment in first episode schizophrenic patients by new pharmacological treatments.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>360 people with a first episode of schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone<BR/>2. Haloperidol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Psychopathology (HAMD, CDSS, PANSS, SANS, CGI, YMRS).<BR/>Adverse events (UKU, EPS, HAS, AIMS).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. Dr. Hans-Jürgen Möller,<BR/>Department of Psychiatry,<BR/>Ludwig-Maximilians-University Munich,<BR/>Nussbaumstr. 7, 80336 Munich, Germany.<BR/>hans-juergen.moeller@psy.med.uni-muenchen.de<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Reveley-2000">
<CHAR_STUDY_NAME>
<P>Ris-int-35 a double blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>26 people with a diagnosis of early psychotic symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone.<BR/>2. Haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Relapse.<BR/>Morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Department of Psychiatry, Clinical Sciences Building, University of Leicester, Leicester Royal Infirmary, PO BOX 65, LE2 7LX, United Kingdom.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Rosebush-2000">
<CHAR_STUDY_NAME>
<P>Olanzapine versus haloperidol in randomised trials of first-episode patients with schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with first-episode schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine.<BR/>2. Haloperdol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neurological and other side effects.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Rosebush, Mazurek, <BR/>McMaster University, Hamilton, Ontario, Canada.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Schooler-1997a">
<CHAR_STUDY_NAME>
<P>The FutuRis study - a prospective long-term evaluation of risperidone versus haloperidol in early psychosis patients.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>500 people with early psychosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone 1-4 mg/d.<BR/>2. Haloperidol 1-4 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PANSS.<BR/>CGI.<BR/>Cognitive function.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Dept Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Sharma-2000">
<CHAR_STUDY_NAME>
<P>A double-blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Approximately 35 people with first episode psychotic disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone.<BR/>2. Haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Dept of Psychological Medicine, Instiute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Sharma-2000a">
<CHAR_STUDY_NAME>
<P>The acute and long-term efficacy of olanzapine in first-episode psychotic disorders: a randomised double-blind comparison with haloperidol.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with first episode psychotic disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine.<BR/>2. Haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Forest Healthcare NHS Trust, Whipps Cross Hospital, Whipps Cross Road, London, E11 1NR, England.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Global effect scales:<BR/>CGI - Clinical Global Impression</P>
<P>Mental state scales:<BR/>PANSS - Positive and Negative Symptoms Scale<BR/>SANS - Scale for Assessment of Negative Symptoms<BR/>HAMD - Hamilton Depression Scale<BR/>CDSS - Calgary Depression Scale for Schizophrenia<BR/>YMRS - Young Mania Rating Scale</P>
<P>Side effect scales:<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>BAS - Barnes Akathisia Scale<BR/>HAS - Hillside Akathisia Scale<BR/>SAS - Simpson and Angus Scale<BR/>UKU - UKU Side effect Scale</P>
<P>Quality of Life:<BR/>LQLP - Lancashire Quality of Life Profile</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Emsley-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanger-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>NEW GENERATION ANTIPSYCHOTICS versus CONVENTIONAL ANTIPSYCHOTICS (HALOPERIDOL)</NAME>
<DICH_OUTCOME CHI2="4.172981074386255" CI_END="0.6613054934527747" CI_START="0.33713042854744674" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47217179543945087" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="60" I2="28.108947859505275" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.17959786960462665" LOG_CI_START="-0.4722020473785939" LOG_EFFECT_SIZE="-0.3258999584916103" METHOD="MH" NO="1" P_CHI2="0.2433810805292591" P_Q="0.0" P_Z="1.2655331900545287E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="216" WEIGHT="400.0" Z="4.365981279324606">
<NAME>Leaving the study early due to any reason</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7302626372766889" CI_START="0.2578082590361013" DF="0.0" EFFECT_SIZE="0.43389830508474575" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.13652091877475608" LOG_CI_START="-0.5887031738858333" LOG_EFFECT_SIZE="-0.36261204633029465" NO="1" P_CHI2="1.0" P_Z="0.0016696793812451863" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="3.143451752626446">
<NAME>due to any reason - olanzapine</NAME>
<DICH_DATA CI_END="0.7302626372766889" CI_START="0.25780825903610133" EFFECT_SIZE="0.43389830508474575" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="-0.13652091877475608" LOG_CI_START="-0.588703173885833" LOG_EFFECT_SIZE="-0.36261204633029465" ORDER="357" O_E="0.0" SE="0.2656140949905089" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.0705508474576271" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0817629948878535" CI_START="0.39379423810647673" DF="0.0" EFFECT_SIZE="0.6526806526806527" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.03413212094882072" LOG_CI_START="-0.4047306426338308" LOG_EFFECT_SIZE="-0.18529926084250503" NO="2" P_CHI2="1.0" P_Z="0.09790514137496205" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="1.655095431876644">
<NAME>due to any reason - risperidone</NAME>
<DICH_DATA CI_END="1.0817629948878535" CI_START="0.39379423810647673" EFFECT_SIZE="0.6526806526806527" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.03413212094882072" LOG_CI_START="-0.4047306426338308" LOG_EFFECT_SIZE="-0.18529926084250503" ORDER="358" O_E="0.0" SE="0.2577901597341653" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.06645576645576647" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8637546039287056" CI_START="0.011973141146255615" DF="0.0" EFFECT_SIZE="0.1016949152542373" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.06360962476332756" LOG_CI_START="-1.9217918977536734" LOG_EFFECT_SIZE="-0.9927007612585005" NO="3" P_CHI2="1.0" P_Z="0.03624647297657143" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.0941516532294076">
<NAME>due to adverse effects - olanzapine</NAME>
<DICH_DATA CI_END="0.8637546039287056" CI_START="0.011973141146255615" EFFECT_SIZE="0.1016949152542373" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="-0.06360962476332756" LOG_CI_START="-1.9217918977536734" LOG_EFFECT_SIZE="-0.9927007612585005" ORDER="359" O_E="0.0" SE="1.0915054653051264" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="1.1913841807909604" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8356119574582366" CI_START="0.13784896813554046" DF="0.0" EFFECT_SIZE="0.3393939393939394" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.07799535397060206" LOG_CI_START="-0.8605964804448095" LOG_EFFECT_SIZE="-0.46929591720770586" NO="4" P_CHI2="1.0" P_Z="0.01874162708052811" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="2.350630646195751">
<NAME>due to adverse effects - risperidone</NAME>
<DICH_DATA CI_END="0.8356119574582366" CI_START="0.13784896813554046" EFFECT_SIZE="0.3393939393939394" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.07799535397060206" LOG_CI_START="-0.8605964804448095" LOG_EFFECT_SIZE="-0.46929591720770586" ORDER="360" O_E="0.0" SE="0.4597037756290036" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.2113275613275613" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.348829923205691E-31" CI_END="1.54203455006731" CI_START="0.6282175387291543" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9842424242424244" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" I2="100.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.18809410441239902" LOG_CI_START="-0.20188994302989852" LOG_EFFECT_SIZE="-0.006897919308749726" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.9447233690821535" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.06933449458808069">
<NAME>Global state: 1. No clinically significant change (CGI &lt; much improved)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.348829923205691E-31" CI_END="1.54203455006731" CI_START="0.6282175387291543" DF="0.0" EFFECT_SIZE="0.9842424242424244" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" I2="100.0" ID="CMP-001.02.01" LOG_CI_END="0.18809410441239902" LOG_CI_START="-0.20188994302989852" LOG_EFFECT_SIZE="-0.006897919308749726" NO="1" P_CHI2="0.0" P_Z="0.9447233690821535" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.06933449458808069">
<NAME>risperidone</NAME>
<DICH_DATA CI_END="1.54203455006731" CI_START="0.6282175387291542" EFFECT_SIZE="0.9842424242424243" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.18809410441239902" LOG_CI_START="-0.20188994302989857" LOG_EFFECT_SIZE="-0.006897919308749775" ORDER="361" O_E="0.0" SE="0.22907855991977435" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.05247698661491765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.113199373138197" CI_START="0.522574304427539" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7627118644067796" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0465729531033469" LOG_CI_START="-0.2818519488369479" LOG_EFFECT_SIZE="-0.11763949786680053" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.1602918358237142" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.404090722817488">
<NAME>Global state: 2. Need of additional medication (at least one dose of benzodiazepine)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.113199373138197" CI_START="0.522574304427539" DF="0.0" EFFECT_SIZE="0.7627118644067796" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.0465729531033469" LOG_CI_START="-0.2818519488369479" LOG_EFFECT_SIZE="-0.11763949786680053" NO="1" P_CHI2="1.0" P_Z="0.1602918358237142" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.404090722817488">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="1.113199373138197" CI_START="0.522574304427539" EFFECT_SIZE="0.7627118644067796" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" LOG_CI_END="0.0465729531033469" LOG_CI_START="-0.2818519488369479" LOG_EFFECT_SIZE="-0.11763949786680053" ORDER="362" O_E="0.0" SE="0.1929184131292132" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.037217514124293784" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.681194836408147" CI_END="0.9236250692274715" CI_START="0.5308522324521274" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7002202724487159" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="54" I2="78.63793251623567" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.03450428788197185" LOG_CI_START="-0.2750263519159187" LOG_EFFECT_SIZE="-0.1547653198989453" METHOD="MH" NO="4" P_CHI2="0.030494607795257367" P_Q="0.0" P_Z="0.011659008497659617" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="158" TOTAL_2="108" WEIGHT="200.0" Z="2.522300432403914">
<NAME>Mental state: 1. General a. No clinically significant improvement - as defined by each of the studies</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7133914346388723" CI_START="0.289734311154794" DF="0.0" EFFECT_SIZE="0.4546360917248255" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.14667210933941507" LOG_CI_START="-0.5380000713725513" LOG_EFFECT_SIZE="-0.34233609035598317" NO="1" P_CHI2="1.0" P_Z="6.054147448110325E-4" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="99.99999999999999" Z="3.429176919635311">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="0.7133914346388723" CI_START="0.289734311154794" EFFECT_SIZE="0.4546360917248255" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="-0.14667210933941507" LOG_CI_START="-0.5380000713725513" LOG_EFFECT_SIZE="-0.34233609035598317" ORDER="363" O_E="0.0" SE="0.22986798200291744" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.05283928915009358" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2051094192068152" CI_START="0.5973951631563889" DF="0.0" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.0810264809360713" LOG_CI_START="-0.22373829800740774" LOG_EFFECT_SIZE="-0.07135590853566824" NO="2" P_CHI2="1.0" P_Z="0.35872890622050324" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.9177898528752313">
<NAME>risperidone</NAME>
<DICH_DATA CI_END="1.2051094192068152" CI_START="0.5973951631563889" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.0810264809360713" LOG_CI_START="-0.22373829800740774" LOG_EFFECT_SIZE="-0.07135590853566824" ORDER="364" O_E="0.0" SE="0.1790203397613859" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.03204828204828205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.103454617237894" CI_END="0.9108507284538272" CI_START="0.5881889232224379" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7319510292264297" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="92" I2="60.81085950593903" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.04055279000895103" LOG_CI_START="-0.23048315838839978" LOG_EFFECT_SIZE="-0.1355179741986754" METHOD="MH" NO="5" P_CHI2="0.07794700089783901" P_Q="0.0" P_Z="0.005159175851602438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="257" TOTAL_2="192" WEIGHT="300.0" Z="2.7969234299234076">
<NAME>Mental state: 1. General b. Various measures of change</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2051094192068152" CI_START="0.5973951631563889" DF="0.0" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.0810264809360713" LOG_CI_START="-0.22373829800740774" LOG_EFFECT_SIZE="-0.07135590853566824" NO="1" P_CHI2="1.0" P_Z="0.35872890622050324" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.9177898528752313">
<NAME>less than 50% PANSS reduction (risperidone)</NAME>
<DICH_DATA CI_END="1.2051094192068152" CI_START="0.5973951631563889" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.0810264809360713" LOG_CI_START="-0.22373829800740774" LOG_EFFECT_SIZE="-0.07135590853566824" ORDER="365" O_E="0.0" SE="0.1790203397613859" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.03204828204828205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7133914346388723" CI_START="0.289734311154794" DF="0.0" EFFECT_SIZE="0.4546360917248255" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.14667210933941507" LOG_CI_START="-0.5380000713725513" LOG_EFFECT_SIZE="-0.34233609035598317" NO="2" P_CHI2="1.0" P_Z="6.054147448110325E-4" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="99.99999999999999" Z="3.429176919635311">
<NAME>less than 40% PANSS reduction (olanzapine)</NAME>
<DICH_DATA CI_END="0.7133914346388723" CI_START="0.289734311154794" EFFECT_SIZE="0.4546360917248255" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="-0.14667210933941507" LOG_CI_START="-0.5380000713725513" LOG_EFFECT_SIZE="-0.34233609035598317" ORDER="366" O_E="0.0" SE="0.22986798200291744" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.05283928915009358" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1150105426724464" CI_START="0.547744599907849" DF="0.0" EFFECT_SIZE="0.7814992025518341" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.04727897375442337" LOG_CI_START="-0.2614218953588289" LOG_EFFECT_SIZE="-0.10707146080220278" NO="3" P_CHI2="1.0" P_Z="0.17395375634709964" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="1.3596087859890038">
<NAME>less than 50% BPRS reduction (risperidone)</NAME>
<DICH_DATA CI_END="1.1150105426724461" CI_START="0.547744599907849" EFFECT_SIZE="0.7814992025518341" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" LOG_CI_END="0.04727897375442329" LOG_CI_START="-0.2614218953588289" LOG_EFFECT_SIZE="-0.10707146080220278" ORDER="367" O_E="0.0" SE="0.18133241861107122" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.03288144603934077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.6760238617550858" CI_END="0.24324279855619668" CI_START="-10.993559645428551" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.375158423436178" ESTIMABLE="YES" I2="62.63112544354727" I2_Q="62.63112544354727" ID="CMP-001.06" NO="6" P_CHI2="0.10186985301666018" P_Q="0.10186985301666018" P_Z="0.06077767520672929" Q="2.6760238617550858" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="1.8751093958711778">
<NAME>Mental state: 1. General c. Average change (PANSS endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.240561850864138" CI_START="-20.15943814913586" DF="0.0" EFFECT_SIZE="-11.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.014281312632810315" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="99.99999999999999" Z="2.450108618581829">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-2.240561850864138" CI_START="-20.15943814913586" EFFECT_SIZE="-11.2" ESTIMABLE="YES" MEAN_1="-27.5" MEAN_2="-16.3" ORDER="368" SD_1="20.5" SD_2="18.1" SE="4.571225910173231" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.612840148084366" CI_START="-8.812840148084362" DF="0.0" EFFECT_SIZE="-1.5999999999999979" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.6637277872490316" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0" Z="0.4347721994222966">
<NAME>risperidone</NAME>
<CONT_DATA CI_END="5.612840148084366" CI_START="-8.812840148084362" EFFECT_SIZE="-1.5999999999999979" ESTIMABLE="YES" MEAN_1="-30.9" MEAN_2="-29.3" ORDER="369" SD_1="24.75" SD_2="24.75" SE="3.6800881061990562" STUDY_ID="STD-Emsley-1999" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.583674918200339" CI_END="-0.18580572911469107" CI_START="-6.848110722630528" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5169582258726098" ESTIMABLE="YES" I2="72.09568326297345" I2_Q="72.09568326297345" ID="CMP-001.07" NO="7" P_CHI2="0.058350099003875666" P_Q="0.058350099003875666" P_Z="0.03851913745100792" Q="3.583674918200339" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="2.0692872705620644">
<NAME>Mental state: 1. General d. Average change (BPRS endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.253776790152065" CI_START="-13.346223209847937" DF="0.0" EFFECT_SIZE="-7.800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.005843795425414985" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0" Z="2.756419729423688">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-2.253776790152065" CI_START="-13.346223209847937" EFFECT_SIZE="-7.800000000000001" ESTIMABLE="YES" MEAN_1="-16.6" MEAN_2="-8.8" ORDER="370" SD_1="12.7" SD_2="11.2" SE="2.8297577167722654" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.0663500985532606" CI_START="-5.266350098553256" DF="0.0" EFFECT_SIZE="-1.0999999999999979" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.6048282422675098" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0" Z="0.5174698073843339">
<NAME>risperidone</NAME>
<CONT_DATA CI_END="3.0663500985532606" CI_START="-5.266350098553256" EFFECT_SIZE="-1.0999999999999979" ESTIMABLE="YES" MEAN_1="-17.9" MEAN_2="-16.8" ORDER="371" SD_1="13.86" SD_2="14.66" SE="2.1257278865412306" STUDY_ID="STD-Emsley-1999" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2212128005762035" CI_END="0.4971490983243896" CI_START="-2.902566619293781" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2027087604846955" ESTIMABLE="YES" I2="68.95579206002402" I2_Q="68.95579206002402" ID="CMP-001.08" NO="8" P_CHI2="0.0726898065263114" P_Q="0.0726898065263114" P_Z="0.16552016732920852" Q="3.2212128005762035" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="1.386742922194863">
<NAME>Mental state: 2. Specific a. Positive symptoms - average change (PANSS positive subscore endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.45937825120609155" CI_START="-6.340621748793907" DF="0.0" EFFECT_SIZE="-3.3999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.02344245946868915" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0" Z="2.266145773481191">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-0.45937825120609155" CI_START="-6.340621748793907" EFFECT_SIZE="-3.3999999999999995" ESTIMABLE="YES" MEAN_1="-8.7" MEAN_2="-5.3" ORDER="372" SD_1="6.6" SD_2="6.0" SE="1.500344787959961" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9831750492766296" CI_START="-2.183175049276629" DF="0.0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="1.0" P_Z="0.9250413025405982" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0" Z="0.0940854195244242">
<NAME>risperidone</NAME>
<CONT_DATA CI_END="1.9831750492766296" CI_START="-2.183175049276629" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="-10.6" MEAN_2="-10.5" ORDER="373" SD_1="6.93" SD_2="7.33" SE="1.0628639432706153" STUDY_ID="STD-Emsley-1999" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6786996643113061" CI_START="-3.2786996643113078" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.19785364794793303" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.2876907121672232">
<NAME>Mental state: 2. Specific b. Positive symptoms - average change (BPRS positive subscore endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6786996643113061" CI_START="-3.2786996643113078" DF="0.0" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.19785364794793303" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0" Z="1.2876907121672232">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="0.6786996643113061" CI_START="-3.2786996643113078" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-4.6" ORDER="374" SD_1="4.3" SD_2="4.1" SE="1.009559195943924" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5939305010968092" CI_END="0.3323326312607555" CI_START="-2.9692699303260106" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3184686495326274" ESTIMABLE="YES" I2="37.262007389162584" I2_Q="37.262007389162584" ID="CMP-001.10" NO="10" P_CHI2="0.2067655223289312" P_Q="0.2067655223289312" P_Z="0.11749103026932618" Q="1.5939305010968092" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="1.5653919692787963">
<NAME>Mental state: 2. Specific c. Negative symptoms - average change (PANSS negative subscore endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.006481813217384058" CI_START="-5.406481813217384" DF="0.0" EFFECT_SIZE="-2.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="1.0" P_Z="0.050551207420404067" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.00000000000001" Z="1.9552700233988611">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="0.006481813217384058" CI_START="-5.406481813217384" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-3.3" ORDER="375" SD_1="5.9" SD_2="5.6" SE="1.380883442025347" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5831750492766292" CI_START="-2.583175049276629" DF="0.0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="1.0" P_Z="0.6380499095860204" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0" Z="0.4704270976221227">
<NAME>risperidone</NAME>
<CONT_DATA CI_END="1.5831750492766292" CI_START="-2.583175049276629" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-5.3" ORDER="376" SD_1="6.93" SD_2="7.33" SE="1.0628639432706153" STUDY_ID="STD-Emsley-1999" TOTAL_1="98" TOTAL_2="84" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.10497128192909155" CI_START="-3.095028718070908" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.035942261192565834" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="2.0975800246235474">
<NAME>Mental state: 2. Specific d. Negative symptoms - average change (BPRS negative subscore endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10497128192909155" CI_START="-3.095028718070908" DF="0.0" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="0.035942261192565834" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0" Z="2.0975800246235474">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-0.10497128192909155" CI_START="-3.095028718070908" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.7" ORDER="377" SD_1="3.0" SD_2="3.2" SE="0.7627837704485919" STUDY_ID="STD-Sanger-1999" TOTAL_1="58" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2092756009619183" CI_START="-7.009275600961919" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.16660761203165253" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.3831867480087354">
<NAME>Mental state: 2. Specific e. Depressive symptoms - average change (MADRS endpoint, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2092756009619183" CI_START="-7.009275600961919" DF="0.0" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="1.0" P_Z="0.16660761203165253" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="18" WEIGHT="100.0" Z="1.3831867480087354">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="1.2092756009619183" CI_START="-7.009275600961919" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-7.9" MEAN_2="-5.0" ORDER="378" SD_1="8.3" SD_2="7.3" SE="2.096607709822915" STUDY_ID="STD-Sanger-1999" TOTAL_1="48" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9751787406513189" CI_START="0.7578063215870572" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.010915775107537665" LOG_CI_START="-0.12044177618041774" LOG_EFFECT_SIZE="-0.06567877564397773" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.018741215575214944" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="2.3506388172654167">
<NAME>Adverse events: 1. General a. At least one adverse event</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9751787406513189" CI_START="0.7578063215870572" DF="0.0" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="76" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-0.010915775107537665" LOG_CI_START="-0.12044177618041774" LOG_EFFECT_SIZE="-0.06567877564397773" NO="1" P_CHI2="1.0" P_Z="0.018741215575214944" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="2.3506388172654167">
<NAME>risperidone</NAME>
<DICH_DATA CI_END="0.9751787406513189" CI_START="0.7578063215870571" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="76" LOG_CI_END="-0.010915775107537665" LOG_CI_START="-0.1204417761804178" LOG_EFFECT_SIZE="-0.06567877564397773" ORDER="379" O_E="0.0" SE="0.064336115192659" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.004139135718083088" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0435195607054335" CI_END="0.7672827946075987" CI_START="0.4902969884071198" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6133485497273996" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" I2="67.14330300646341" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.11504454022068765" LOG_CI_START="-0.30954077434955185" LOG_EFFECT_SIZE="-0.21229265728511973" METHOD="MH" NO="14" P_CHI2="0.08106021934337504" P_Q="0.0" P_Z="1.880710261219732E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="158" TOTAL_2="108" WEIGHT="200.0" Z="4.278601735655819">
<NAME>Adverse events: 2. Extrapyramdial problems a. General i. Needing anticholinergic medication at least once</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9632508536527818E-31" CI_END="0.7238626596157783" CI_START="0.1462993039745031" DF="0.0" EFFECT_SIZE="0.32542372881355935" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="99.99999999999999" ID="CMP-001.14.01" LOG_CI_END="-0.14034382583194882" LOG_CI_START="-0.8347577400452402" LOG_EFFECT_SIZE="-0.48755078293859455" NO="1" P_CHI2="0.0" P_Z="0.005919688316844006" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.7521970848655575">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="0.723862659615778" CI_START="0.14629930397450308" EFFECT_SIZE="0.3254237288135593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="-0.14034382583194904" LOG_CI_START="-0.8347577400452403" LOG_EFFECT_SIZE="-0.48755078293859466" ORDER="380" O_E="0.0" SE="0.4079021706132004" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.16638418079096046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8482237183129004" CI_START="0.5346095106116815" DF="0.0" EFFECT_SIZE="0.6734006734006734" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-0.0714895878201961" LOG_CI_START="-0.2719633194862661" LOG_EFFECT_SIZE="-0.17172645365323114" NO="2" P_CHI2="1.0" P_Z="7.855886935293419E-4" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="3.357823107854935">
<NAME>risperidone</NAME>
<DICH_DATA CI_END="0.8482237183129004" CI_START="0.5346095106116815" EFFECT_SIZE="0.6734006734006734" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" LOG_CI_END="-0.0714895878201961" LOG_CI_START="-0.2719633194862661" LOG_EFFECT_SIZE="-0.17172645365323114" ORDER="381" O_E="0.0" SE="0.11775926234162588" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.013867243867243868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7870483942342394" CI_START="0.17029505682458976" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36610169491525424" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.1039985628090259" LOG_CI_START="-0.7687979581734006" LOG_EFFECT_SIZE="-0.43639826049121333" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.010076824166054403" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.573181863409806">
<NAME>Adverse events: 2. Extrapyramdial problems a. General ii. Not improved (SAS total &gt;3)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7870483942342394" CI_START="0.17029505682458976" DF="0.0" EFFECT_SIZE="0.36610169491525424" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-0.1039985628090259" LOG_CI_START="-0.7687979581734006" LOG_EFFECT_SIZE="-0.43639826049121333" NO="1" P_CHI2="1.0" P_Z="0.010076824166054403" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.573181863409806">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="0.7870483942342393" CI_START="0.17029505682458976" EFFECT_SIZE="0.36610169491525424" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="-0.10399856280902596" LOG_CI_START="-0.7687979581734006" LOG_EFFECT_SIZE="-0.43639826049121333" ORDER="382" O_E="0.0" SE="0.39050645564711417" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.15249529190207156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.9220184068792072" CI_START="-8.077981593120793" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.0014533222090346836" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="3.1838461752346436">
<NAME>Adverse events: 2. Extrapyramdial problems a. General iii. Average change (SAS, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.9220184068792072" CI_START="-8.077981593120793" DF="0.0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="1.0" P_Z="0.0014533222090346836" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="3.1838461752346436">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-1.9220184068792072" CI_START="-8.077981593120793" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="4.5" ORDER="383" SD_1="3.3" SD_2="7.4" SE="1.5704276289766133" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6186272194039474" CI_START="0.04912876699926798" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17433414043583534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.20857097509122025" LOG_CI_START="-1.308664135359045" LOG_EFFECT_SIZE="-0.7586175552251326" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.006868398649346501" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.00000000000001" Z="2.703158495993374">
<NAME>Adverse events: 2. Extrapyramdial problems b. Specific i. Akathisia</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6186272194039474" CI_START="0.04912876699926798" DF="0.0" EFFECT_SIZE="0.17433414043583534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="-0.20857097509122025" LOG_CI_START="-1.308664135359045" LOG_EFFECT_SIZE="-0.7586175552251326" NO="1" P_CHI2="1.0" P_Z="0.006868398649346501" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.00000000000001" Z="2.703158495993374">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="0.6186272194039473" CI_START="0.04912876699926799" EFFECT_SIZE="0.17433414043583534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.20857097509122033" LOG_CI_START="-1.3086641353590447" LOG_EFFECT_SIZE="-0.7586175552251326" ORDER="384" O_E="0.0" SE="0.6462001678902881" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.4175746569814366" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.07831274596224969" CI_START="-1.1216872540377503" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.024184675727720265" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="2.2541827150696236">
<NAME>Adverse events: 2. Extrapyramdial problems b. Specific ii. Akathisia - average change (BAS, low=poor)</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.07831274596224969" CI_START="-1.1216872540377503" DF="0.0" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="1.0" P_Z="0.024184675727720265" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.2541827150696236">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-0.07831274596224969" CI_START="-1.1216872540377503" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.5" ORDER="385" SD_1="0.8" SD_2="1.2" SE="0.2661718573161307" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5030888377178737" CI_END="0.48449126463201414" CI_START="0.09198039679899597" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21110115766262402" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.3147140488636056" LOG_CI_START="-1.0363047212324892" LOG_EFFECT_SIZE="-0.6755093850480474" METHOD="MH" NO="19" P_CHI2="0.4716376914173138" P_Q="0.0" P_Z="2.4293161054859117E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="177" TOTAL_2="72" WEIGHT="300.0" Z="3.669598614867198">
<NAME>Adverse Events: 2. Extrapyramdial problems b. Specific iii. Others</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5222250867004663" CI_START="0.04831222809958538" DF="0.0" EFFECT_SIZE="0.2711864406779661" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.18247887496038992" LOG_CI_START="-1.3159429329328285" LOG_EFFECT_SIZE="-0.5667320289862194" NO="1" P_CHI2="1.0" P_Z="0.1381827469767345" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.4825923646427024">
<NAME>extrapyramidal syndrome - olanzapine</NAME>
<DICH_DATA CI_END="1.5222250867004663" CI_START="0.04831222809958538" EFFECT_SIZE="0.2711864406779661" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.18247887496038992" LOG_CI_START="-1.3159429329328285" LOG_EFFECT_SIZE="-0.5667320289862194" ORDER="386" O_E="0.0" SE="0.8801803872640505" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.7747175141242938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8261201802699673" CI_START="0.10219253151779673" DF="0.0" EFFECT_SIZE="0.29055690072639223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="-0.08295676886430484" LOG_CI_START="-0.9905808423532476" LOG_EFFECT_SIZE="-0.5367688056087763" NO="2" P_CHI2="1.0" P_Z="0.02043600464226342" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.00000000000001" Z="2.318245092318168">
<NAME>hypertonia - olanzapine</NAME>
<DICH_DATA CI_END="0.8261201802699673" CI_START="0.10219253151779673" EFFECT_SIZE="0.29055690072639223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="-0.08295676886430484" LOG_CI_START="-0.9905808423532476" LOG_EFFECT_SIZE="-0.5367688056087763" ORDER="387" O_E="0.0" SE="0.5331428735790279" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.2842413236481033" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8282466515511453" CI_START="0.002587812515438951" DF="0.0" EFFECT_SIZE="0.046296296296296294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="-0.08184031121515434" LOG_CI_START="-2.5870671910867076" LOG_EFFECT_SIZE="-1.334453751150931" NO="3" P_CHI2="1.0" P_Z="0.036796075513142755" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="2.088019502189199">
<NAME>hypokinesia - olanzapine</NAME>
<DICH_DATA CI_END="0.8282466515511453" CI_START="0.002587812515438951" EFFECT_SIZE="0.046296296296296294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.08184031121515434" LOG_CI_START="-2.5870671910867076" LOG_EFFECT_SIZE="-1.334453751150931" ORDER="388" O_E="0.0" SE="1.4715826703096078" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="2.1655555555555557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.26523974090623" CI_END="1.6785935265330927" CI_START="0.8118176706183353" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1673525117226211" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="44" I2="26.62189904055617" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.22494554393115695" LOG_CI_START="-0.09054149974389655" LOG_EFFECT_SIZE="0.06720202209363021" METHOD="MH" NO="20" P_CHI2="0.1987661053275469" P_Q="0.0" P_Z="0.40372591799712476" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="750" TOTAL_2="480" WEIGHT="1000.0" Z="0.8349854336803957">
<NAME>Adverse events: 3. Others</NAME>
<GROUP_LABEL_1>new generation</GROUP_LABEL_1>
<GROUP_LABEL_2>conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8679078424480493" CI_START="0.30452832414880854" DF="0.0" EFFECT_SIZE="0.7542087542087542" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.27135544550029084" LOG_CI_START="-0.5163723074663897" LOG_EFFECT_SIZE="-0.12250843098304953" NO="1" P_CHI2="1.0" P_Z="0.542105461207232" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.6096322279493034">
<NAME>agitation - risperidone</NAME>
<DICH_DATA CI_END="1.8679078424480493" CI_START="0.30452832414880854" EFFECT_SIZE="0.7542087542087542" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.27135544550029084" LOG_CI_START="-0.5163723074663897" LOG_EFFECT_SIZE="-0.12250843098304953" ORDER="389" O_E="0.0" SE="0.46271518140789275" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.21410533910533908" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.562658391506598" CI_START="0.3669284271973028" DF="0.0" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.4086907175492459" LOG_CI_START="-0.4354186406652089" LOG_EFFECT_SIZE="-0.01336396155798149" NO="2" P_CHI2="1.0" P_Z="0.9505147302552723" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.06206040269433178">
<NAME>anxiety/nervousness - risperidone</NAME>
<DICH_DATA CI_END="2.5626583915065977" CI_START="0.36692842719730284" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.40869071754924585" LOG_CI_START="-0.43541864066520886" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="390" O_E="0.0" SE="0.4958340154238824" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.24585137085137082" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5222250867004663" CI_START="0.04831222809958538" DF="0.0" EFFECT_SIZE="0.2711864406779661" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="0.18247887496038992" LOG_CI_START="-1.3159429329328285" LOG_EFFECT_SIZE="-0.5667320289862194" NO="3" P_CHI2="1.0" P_Z="0.1381827469767345" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.4825923646427024">
<NAME>anxiety/nervousness - olanzapine</NAME>
<DICH_DATA CI_END="1.5222250867004663" CI_START="0.04831222809958538" EFFECT_SIZE="0.2711864406779661" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.18247887496038992" LOG_CI_START="-1.3159429329328285" LOG_EFFECT_SIZE="-0.5667320289862194" ORDER="391" O_E="0.0" SE="0.8801803872640505" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.7747175141242938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.87606531660876" CI_START="0.4788775622150182" DF="0.0" EFFECT_SIZE="7.916666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="2.1168602298100443" LOG_CI_START="-0.31977551132759835" LOG_EFFECT_SIZE="0.8985423592412229" NO="4" P_CHI2="1.0" P_Z="0.1483100791368726" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.44552641411572">
<NAME>asthenia - olanzapine</NAME>
<DICH_DATA CI_END="130.87606531660876" CI_START="0.4788775622150182" EFFECT_SIZE="7.916666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1168602298100443" LOG_CI_START="-0.31977551132759835" LOG_EFFECT_SIZE="0.8985423592412229" ORDER="392" O_E="0.0" SE="1.431291895885696" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="2.04859649122807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.20963989011251" CI_START="0.3100999794004686" DF="0.0" EFFECT_SIZE="2.440677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.20.05" LOG_CI_END="1.2835192235184918" LOG_CI_START="-0.5084982626122806" LOG_EFFECT_SIZE="0.3875104804531055" NO="5" P_CHI2="1.0" P_Z="0.39662995994237826" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="0.8476553283637709">
<NAME>dizzyness - olanzapine</NAME>
<DICH_DATA CI_END="19.20963989011249" CI_START="0.3100999794004687" EFFECT_SIZE="2.440677966101695" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2835192235184913" LOG_CI_START="-0.5084982626122805" LOG_EFFECT_SIZE="0.3875104804531055" ORDER="393" O_E="0.0" SE="1.0526399419828354" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="1.1080508474576272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.87606531660876" CI_START="0.4788775622150182" DF="0.0" EFFECT_SIZE="7.916666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-001.20.06" LOG_CI_END="2.1168602298100443" LOG_CI_START="-0.31977551132759835" LOG_EFFECT_SIZE="0.8985423592412229" NO="6" P_CHI2="1.0" P_Z="0.1483100791368726" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.44552641411572">
<NAME>headache - olanzapine</NAME>
<DICH_DATA CI_END="130.87606531660876" CI_START="0.4788775622150182" EFFECT_SIZE="7.916666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1168602298100443" LOG_CI_START="-0.31977551132759835" LOG_EFFECT_SIZE="0.8985423592412229" ORDER="394" O_E="0.0" SE="1.431291895885696" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="2.04859649122807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5648498428734268" CI_START="0.4385774157188424" DF="0.0" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-001.20.07" LOG_CI_END="0.4090619447615361" LOG_CI_START="-0.35795373581675993" LOG_EFFECT_SIZE="0.025554104472388137" NO="7" P_CHI2="1.0" P_Z="0.8960938045848996" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="0.1305973937463513">
<NAME>headache - risperidone</NAME>
<DICH_DATA CI_END="2.564849842873427" CI_START="0.43857741571884234" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.40906194476153623" LOG_CI_START="-0.35795373581676" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="395" O_E="0.0" SE="0.4505488075605439" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.202994227994228" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.122922924093492" CI_START="0.3612066635664827" DF="0.0" EFFECT_SIZE="1.2203389830508475" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.20.08" LOG_CI_END="0.6152052159670708" LOG_CI_START="-0.4422442463888221" LOG_EFFECT_SIZE="0.0864804847891243" NO="8" P_CHI2="1.0" P_Z="0.7485286086958116" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="0.32058011580926316">
<NAME>insomnia - olanzapine</NAME>
<DICH_DATA CI_END="4.122922924093491" CI_START="0.3612066635664827" EFFECT_SIZE="1.2203389830508475" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.6152052159670706" LOG_CI_START="-0.4422442463888221" LOG_EFFECT_SIZE="0.0864804847891243" ORDER="396" O_E="0.0" SE="0.6211510486471103" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="0.38582862523540484" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4116587171313748" CI_START="0.3017670129571397" DF="0.0" EFFECT_SIZE="0.6526806526806527" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-001.20.09" LOG_CI_END="0.14972971429249526" LOG_CI_START="-0.5203282359775052" LOG_EFFECT_SIZE="-0.18529926084250503" NO="9" P_CHI2="1.0" P_Z="0.27835360819307686" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.0" Z="1.0840252771177756">
<NAME>insomnia - risperidone</NAME>
<DICH_DATA CI_END="1.4116587171313748" CI_START="0.3017670129571397" EFFECT_SIZE="0.6526806526806527" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.14972971429249526" LOG_CI_START="-0.5203282359775052" LOG_EFFECT_SIZE="-0.18529926084250503" ORDER="397" O_E="0.0" SE="0.3935953568289455" STUDY_ID="STD-Emsley-1999" TOTAL_1="99" TOTAL_2="84" VAR="0.15491730491730493" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="156.45112574316047" CI_START="0.5870221600613365" DF="0.0" EFFECT_SIZE="9.583333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" ID="CMP-001.20.10" LOG_CI_END="2.1943786924568602" LOG_CI_START="-0.23134550384488614" LOG_EFFECT_SIZE="0.9815165943059869" NO="10" P_CHI2="1.0" P_Z="0.11271352243882621" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="24" WEIGHT="100.0" Z="1.586113687616318">
<NAME>somnolence - olanzapine</NAME>
<DICH_DATA CI_END="156.45112574316047" CI_START="0.5870221600613365" EFFECT_SIZE="9.583333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.1943786924568602" LOG_CI_START="-0.23134550384488614" LOG_EFFECT_SIZE="0.9815165943059869" ORDER="398" O_E="0.0" SE="1.4248824004360723" STUDY_ID="STD-Sanger-1999" TOTAL_1="59" TOTAL_2="24" VAR="2.0302898550724637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>